Ace (angiotensin I converting enzyme) - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Gene: Ace (angiotensin I converting enzyme) Rattus norvegicus
Analyze
Symbol: Ace
Name: angiotensin I converting enzyme
RGD ID: 2493
Description: Enables heterocyclic compound binding activity; metallopeptidase activity; and peptidyl-dipeptidase activity. Involved in several processes, including blood vessel diameter maintenance; negative regulation of transport; and response to corticosteroid. Located in several cellular components, including basal plasma membrane; brush border membrane; and sperm midpiece. Used to study several diseases, including artery disease (multiple); glomerulonephritis (multiple); kidney failure (multiple); lung disease (multiple); and proteinuria (multiple). Biomarker of several diseases, including artery disease (multiple); congenital diaphragmatic hernia; endomyocardial fibrosis; liver cirrhosis (multiple); and lung disease (multiple). Human ortholog(s) of this gene implicated in several diseases, including artery disease (multiple); autoimmune disease (multiple); gastrointestinal system cancer (multiple); heart valve disease (multiple); and lung disease (multiple). Orthologous to human ACE (angiotensin I converting enzyme); PARTICIPATES IN angiotensin (1-7) signaling pathway; renin-angiotensin cascade pathway; angiotensin II signaling pathway; INTERACTS WITH (+)-pilocarpine; (+)-schisandrin B; (R)-lipoic acid.
Type: protein-coding
RefSeq Status: PROVISIONAL
Previously known as: angiotensin 1 converting enzyme; angiotensin 1 converting enzyme 1; angiotensin converting enzyme; angiotensin I converting enzyme (peptidyl-dipeptidase A) 1; angiotensin I converting enzyme 1; angiotensin I-converting enzyme (Dipeptidyl carboxypeptidase 1); angiotensin-converting enzyme; angiotensin-converting enzyme-like; CD143; Dcp1; Dipeptidyl carboxypeptidase 1; Dipeptidyl carboxypeptidase 1 (Angiotensin I-converting enzyme); dipeptidyl carboxypeptidase I; kininase II; LOC102556346; StsRR92
RGD Orthologs
Human
Mouse
Bonobo
Dog
Squirrel
Pig
Naked Mole-Rat
Alliance Genes
More Info more info ...
Allele / Splice: Aceem1Mcwi   Aceem2Mcwi  
Genetic Models: SS-Aceem1Mcwi SS-Aceem2Mcwi
Is Marker For: Strains:   SD-Tg(Ren2)27   SS.MNS-(D10M11Mit119-D10Mit11)/Jr   LOU.BN-(D10Mgh1-D10Mgh14)/Ins  
QTLs:   Bp9   Bw57   Bp342   Bw102  
Candidate Gene For: Bp1 Bp9 Bp72 Bp128 Bp342
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr81091,410,129 - 91,430,246 (+)NCBIGRCr8
mRatBN7.21090,910,316 - 90,930,437 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1090,910,316 - 90,931,131 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1095,964,627 - 95,984,783 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01095,427,801 - 95,447,951 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01090,839,016 - 90,859,102 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01094,170,766 - 94,213,831 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1094,170,766 - 94,187,822 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01093,922,062 - 93,965,127 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41095,361,338 - 95,381,455 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
Celera1089,588,544 - 89,608,666 (+)NCBICelera
Cytogenetic Map10q32.1NCBI
JBrowse: View Region in Genome Browser (JBrowse)
Model


Disease Annotations     Click to see Annotation Detail View
abdominal aortic aneurysm  (IMP)
Acute Hepatitis  (IEP)
acute kidney failure  (IMP)
Acute Lung Injury  (ISO)
adenocarcinoma  (ISO)
adult respiratory distress syndrome  (ISO)
Albuminuria  (IMP,ISO)
alcoholic cardiomyopathy  (ISO)
Alcoholic Liver Diseases  (ISO)
allergic disease  (ISO)
allergic rhinitis  (ISO)
Alzheimer's disease  (IMP,ISO)
anemia  (ISO)
Angiotensin I-Converting Enzyme, Benign Serum Increase  (ISO)
ankylosing spondylitis  (ISO)
Aortic Coarctation  (IEP)
Arteriovenous Fistula  (IEP,IMP)
aspiration pneumonia  (ISO)
asthma  (ISO)
atrial fibrillation  (ISO)
autistic disorder  (ISO)
autosomal recessive polycystic kidney disease  (IEP,IMP)
Banti's Syndrome  (ISO)
Behcet's disease  (ISO)
berylliosis  (ISO)
bipolar disorder  (IEA)
brain ischemia  (ISO)
breast cancer  (ISO)
bronchiolitis obliterans  (IMP)
CAKUT  (ISO)
Cardiac Arrhythmias  (ISO)
Cardiomegaly  (IMP)
cardiovascular system disease  (ISO)
carotid artery disease  (ISO)
celiac disease  (ISO)
Cerebral Hemorrhage  (ISO)
cerebral infarction  (ISO)
Chemical and Drug Induced Liver Injury  (IEP)
chemical colitis  (ISO)
Chemotherapy-Induced Febrile Neutropenia  (ISO)
cholestasis  (IEP)
Chronic Hepatitis C  (IEP,ISO)
Chronic Intermittent Hypoxia  (IEP)
chronic myeloid leukemia  (ISO)
chronic obstructive pulmonary disease  (ISO)
congenital diaphragmatic hernia  (IEP)
Congenital Hepatic Fibrosis  (IEP)
congestive heart failure  (IEP,IMP,ISO)
coronary artery disease  (ISO)
Coronary Disease  (ISO)
coronary restenosis  (ISO)
Coronavirus infectious disease  (ISO)
Cough  (ISO)
COVID-19  (ISO)
Cytomegalovirus Infections  (ISO)
diabetic angiopathy  (ISO)
Diabetic Cardiomyopathies  (IEP)
Diabetic Nephropathies  (IDA,IMP,ISO)
diabetic retinopathy  (ISO)
diastolic heart failure  (IMP,ISO)
diffuse cystic renal dysplasia  (ISO)
dilated cardiomyopathy  (ISO)
drug allergy  (ISO)
end stage renal disease  (IMP,ISO)
endomyocardial fibrosis  (IEP)
Endotoxemia  (IEP)
Experimental Arthritis  (IEP)
Experimental Colitis  (ISO)
Experimental Diabetes Mellitus  (IEP,ISO)
Experimental Liver Cirrhosis  (IEP)
extrinsic allergic alveolitis  (ISO)
Fabry disease  (ISO)
Familial Cerebral Cavernous Malformation  (ISO)
familial mediterranean fever  (ISO)
Fetal Death  (ISO)
Fetal Growth Retardation  (IEP)
focal segmental glomerulosclerosis 1  (IMP)
gallbladder adenocarcinoma  (ISO)
Gaucher's disease  (ISO)
genetic disease  (ISO)
Genetic Predisposition to Disease  (ISO)
glomerulonephritis  (IMP)
glomerulosclerosis  (IMP)
glycogen storage disease V  (ISO)
heart valve disease  (ISO)
Helicobacter Infections  (ISO)
Henoch-Schoenlein purpura  (ISO)
hepatitis A  (ISO)
hepatocellular carcinoma  (ISO)
Hyperoxia  (IEP)
hypertension  (IDA,IEP,IMP,ISO)
Hypertensive Nephrosclerosis  (IMP,ISO)
hypertrophic cardiomyopathy  (ISO)
Hypotension  (ISO)
IgA glomerulonephritis  (ISO)
in situ carcinoma  (ISO)
Insulin Resistance  (ISO)
intermediate coronary syndrome  (ISO)
Intestinal Reperfusion Injury  (IEP)
intracranial aneurysm  (ISO)
kidney disease  (ISO)
kidney failure  (ISO)
Kidney Reperfusion Injury  (IMP)
Left Ventricular Hypertrophy  (IEP,IMP,ISO)
leukemia  (ISO)
leukostasis  (IMP)
liver cirrhosis  (IEP,ISO)
Liver Metastasis  (ISO)
lung cancer  (ISO)
lung carcinoma  (ISO)
lung disease  (IEP,IMP,ISO)
Lung Injury  (ISO)
Lung Neoplasms  (ISO)
malaria  (ISO)
male infertility  (ISO)
Memory Disorders  (IMP,ISO)
Meningococcal Infections  (ISO)
metabolic dysfunction-associated steatotic liver disease  (ISO)
microcephaly  (ISO)
middle cerebral artery infarction  (IMP)
mitral valve disease  (ISO)
mitral valve prolapse  (ISO)
multiple myeloma  (ISO)
Mycobacterium Infections  (ISO)
myocardial infarction  (IEP,IMP,ISO)
myocarditis  (IMP)
Neoplasm Metastasis  (ISO)
nephritis  (ISO)
nephrosis  (IEP,IMP)
nephrotic syndrome  (IDA,IMP)
non-arteritic anterior ischemic optic neuropathy  (ISO)
obesity  (IEP,ISO)
obstructive sleep apnea  (IEP,ISO)
ocular hypotension  (IMP)
osteoporosis  (IMP)
Pain  (IMP)
pancreatic cancer  (ISO)
pancreatic ductal carcinoma  (ISO)
Parkinson's disease  (ISO)
Peritoneal Fibrosis  (IMP,ISO)
Pleural Effusion  (ISO)
pneumonia  (ISO)
polycythemia  (ISO)
pre-eclampsia  (ISO)
pre-malignant neoplasm  (IMP)
Pregnancy-Induced Hypertension  (IEP)
Premature Infant Diseases  (ISO)
Prenatal Exposure Delayed Effects  (IEP)
primary biliary cholangitis  (IEP)
Prostatic Neoplasms  (ISO)
proteinuria  (IMP,ISO)
pulmonary fibrosis  (IEP,IMP,ISO)
pulmonary hypertension  (ISO)
Puromycin Aminonucleoside Nephrosis  (IMP)
pyelonephritis  (ISO)
Radiation Nephropathy  (IMP)
renal fibrosis  (IMP,ISO)
Renal Tubular Dysgenesis  (ISO)
renovascular hypertension  (IDA,IEP)
Reperfusion Injury  (IMP)
respiratory system disease  (ISO)
Right Ventricular Hypertrophy  (IEP)
sarcoidosis  (ISO)
schizophrenia  (ISO)
Sepsis  (ISO)
severe acute respiratory syndrome  (ISO)
Staphylococcal Infections  (ISO)
stomach cancer  (ISO)
Stomach Neoplasms  (ISO)
Stroke  (IMP,ISO)
subacute sclerosing panencephalitis  (ISO)
substance-induced psychosis  (ISO)
Sudden Death  (ISO)
systemic lupus erythematosus  (ISO)
systemic scleroderma  (ISO)
toxic shock syndrome  (ISO)
type 1 diabetes mellitus  (ISO)
type 2 diabetes mellitus  (ISO)
ureteral obstruction  (IMP)
uveitis  (ISO)
Vascular System Injuries  (IAGP,ISO)
Venous Thromboembolism  (ISO)
Ventricular Fibrillation  (IMP)
Ventricular Remodeling  (IDA)
viral pneumonia  (ISO)
Weight Gain  (ISO)
Weight Loss  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(+)-pilocarpine  (EXP)
(+)-schisandrin B  (EXP)
(+)-trans-(S)-allethrin  (ISO)
(-)-epigallocatechin 3-gallate  (ISO)
(R)-lipoic acid  (EXP,ISO)
(S)-colchicine  (EXP)
(S)-nicotine  (ISO)
(S,S,S)-nicotianamine  (ISO)
1,10-phenanthroline  (ISO)
1,2-dimethylhydrazine  (ISO)
14,15-EET  (EXP)
17alpha-ethynylestradiol  (ISO)
17beta-estradiol  (EXP)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,5-dihydroxybenzoic acid  (ISO)
3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine  (EXP)
3,3',5-triiodo-L-thyronine  (EXP)
3-\{1-[3-(dimethylamino)propyl]-1H-indol-3-yl\}-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione  (ISO)
3-chloropropane-1,2-diol  (EXP)
4,4'-sulfonyldiphenol  (ISO)
4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile  (EXP)
4-hydroxyphenyl retinamide  (ISO)
6-propyl-2-thiouracil  (EXP)
7,9-dihydro-1H-purine-2,6,8(3H)-trione  (ISO)
Ac-Ser-Asp-Lys-Pro-OH  (ISO)
acetamide  (EXP)
acetylsalicylic acid  (ISO)
acrylamide  (ISO)
actinomycin D  (EXP)
aldehydo-D-glucose  (EXP,ISO)
aldosterone  (EXP)
aluminium atom  (ISO)
aluminium(0)  (ISO)
aminoguanidine  (ISO)
amitrole  (EXP)
amlodipine  (EXP)
ammonium chloride  (EXP)
antirheumatic drug  (ISO)
arsenite(3-)  (ISO)
atorvastatin calcium  (EXP)
atrazine  (ISO)
benazepril  (ISO)
benzo[a]pyrene  (EXP,ISO)
beta-naphthoflavone  (EXP)
bezafibrate  (EXP)
bis(2-chloroethyl) sulfide  (EXP,ISO)
bisphenol A  (EXP,ISO)
bleomycin A2  (EXP)
boric acid  (ISO)
bortezomib  (ISO)
Butralin  (EXP)
cadmium dichloride  (EXP)
caffeine  (EXP)
candesartan  (EXP)
cannabidiol  (ISO)
captan  (ISO)
captopril  (EXP,ISO)
carbon nanotube  (ISO)
carvedilol  (EXP,ISO)
chromium atom  (EXP)
chromium(6+)  (ISO)
cilazapril monohydrate  (ISO)
cobalt dichloride  (ISO)
cocaine  (ISO)
corticosterone  (EXP)
Cuprizon  (EXP)
curcumin  (EXP)
cyclophosphamide  (EXP)
D-glucose  (EXP,ISO)
DDT  (EXP)
dexamethasone  (EXP,ISO)
dextran sulfate  (ISO)
diisononyl phthalate  (ISO)
dioxygen  (ISO)
doxorubicin  (EXP)
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor  (EXP)
enalapril  (EXP,ISO)
enalaprilat dihydrate  (ISO)
ethanol  (EXP)
ethylbenzene  (ISO)
ethylenediaminetetraacetic acid  (ISO)
fenvalerate  (ISO)
flavonoids  (EXP)
folic acid  (EXP,ISO)
folpet  (ISO)
formaldehyde  (ISO)
fructose  (EXP)
furan  (EXP)
genistein  (EXP)
gentamycin  (EXP)
glucose  (EXP,ISO)
glycidol  (EXP)
goralatide  (ISO)
GW 4064  (ISO)
herbimycin  (ISO)
hydralazine  (EXP)
hydrazines  (ISO)
hydrochlorothiazide  (EXP)
hydrogen peroxide  (ISO)
indometacin  (ISO)
indoxyl sulfate  (EXP)
inulin  (ISO)
isoprenaline  (EXP)
ketamine  (EXP)
L-ascorbic acid  (ISO)
Lasiocarpine  (ISO)
lead diacetate  (EXP)
lead(0)  (EXP)
lipoic acid  (EXP,ISO)
lisinopril dihydrate  (ISO)
lithium chloride  (EXP)
losartan  (EXP,ISO)
lycopene  (EXP)
Magnolol  (EXP)
maneb  (ISO)
manganese(II) chloride  (EXP)
manidipine  (EXP)
metformin  (ISO)
methoxychlor  (EXP)
metoprolol  (ISO)
microcystin RR  (ISO)
mifepristone  (EXP)
monocrotaline  (EXP)
N(4)-hydroxycytidine  (ISO)
N(gamma)-nitro-L-arginine methyl ester  (EXP)
N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal  (ISO)
N-methylnicotinate  (EXP,ISO)
N-nitrosodiethylamine  (EXP)
Nandrolone decanoate  (EXP)
naringin  (EXP)
nicotianamine  (ISO)
nicotinamide  (ISO)
nicotine  (ISO)
nicotinic acid  (EXP)
nitric oxide  (EXP)
nitrofen  (EXP)
NS-398  (ISO)
oleuropein  (EXP)
oltipraz  (EXP,ISO)
omapatrilat  (ISO)
ouabain  (EXP)
ozone  (ISO)
paracetamol  (EXP,ISO)
paraquat  (EXP,ISO)
perfluorooctane-1-sulfonic acid  (ISO)
perindopril  (ISO)
phenylephrine  (ISO)
phorbol 13-acetate 12-myristate  (ISO)
pioglitazone  (EXP)
pirfenidone  (EXP)
pirinixic acid  (ISO)
potassium dichromate  (ISO)
pravastatin  (EXP)
pregabalin  (EXP)
proanthocyanidin  (EXP)
prostaglandin E2  (ISO)
prostaglandin I2  (ISO)
quercetin  (EXP,ISO)
quinapril hydrochloride  (EXP,ISO)
raloxifene  (ISO)
ramipril  (EXP,ISO)
rebaudioside A  (ISO)
resveratrol  (EXP,ISO)
rivastigmine  (EXP)
silicon dioxide  (ISO)
silver atom  (EXP)
silver(0)  (EXP)
sodium arsenite  (ISO)
sodium chloride  (ISO)
sodium dichromate  (EXP)
sodium fluoride  (ISO)
spironolactone  (EXP)
steviol  (ISO)
stevioside  (ISO)
streptozocin  (EXP,ISO)
sunitinib  (ISO)
telmisartan  (EXP)
testosterone  (EXP,ISO)
tetrachloromethane  (EXP)
titanium dioxide  (EXP,ISO)
toluene  (ISO)
trandolapril  (EXP)
tributylstannane  (ISO)
triclosan  (ISO)
triptonide  (ISO)
tyrphostin AG 1478  (EXP)
valproic acid  (ISO)
valsartan  (EXP)
venlafaxine hydrochloride  (EXP)
vinclozolin  (EXP)
zinc atom  (ISO)
zinc sulfate  (ISO)
zinc(0)  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process
amyloid-beta metabolic process  (IEA,ISO)
angiogenesis involved in coronary vascular morphogenesis  (IMP)
angiotensin maturation  (IEA,ISO,ISS)
angiotensin-activated signaling pathway  (IEA,ISO)
animal organ regeneration  (IMP)
arachidonic acid secretion  (IEA,ISO)
bradykinin catabolic process  (IDA,IEA,IMP,ISO)
cell proliferation in bone marrow  (IEA,ISO)
cellular response to aldosterone  (IEP)
cellular response to glucose stimulus  (IEP)
eating behavior  (IMP)
embryo development ending in birth or egg hatching  (IMP)
female pregnancy  (IEP)
heart contraction  (IEA,ISO)
hormone catabolic process  (IEA,ISO,ISS)
hormone metabolic process  (ISO,ISS)
kidney development  (IEA,IEP,ISO,ISS)
lung alveolus development  (IMP)
lung development  (IEP)
male gonad development  (IEA,IEP,ISO)
negative regulation of calcium ion import  (IMP)
negative regulation of gap junction assembly  (IEA,ISO)
negative regulation of gene expression  (IEA,ISO)
negative regulation of glucose import  (IMP)
neutrophil mediated immunity  (IEA,ISO)
peptide catabolic process  (IDA,ISO)
peptide metabolic process  (IMP)
positive regulation of apoptotic process  (IMP)
positive regulation of blood pressure  (IMP)
positive regulation of neurogenesis  (IMP)
positive regulation of peptidyl-cysteine S-nitrosylation  (IEA,ISO)
positive regulation of systemic arterial blood pressure  (IBA,IEA,IMP,ISO)
positive regulation of vasoconstriction  (IMP)
post-transcriptional regulation of gene expression  (IEA,ISO)
proteolysis  (IEA)
regulation of angiotensin metabolic process  (IEA,ISO)
regulation of blood pressure  (IDA,ISO,TAS)
regulation of heart rate by cardiac conduction  (IEA,ISO)
regulation of hematopoietic stem cell proliferation  (IEA,ISO)
regulation of smooth muscle cell migration  (IDA)
regulation of synaptic plasticity  (IEA,ISO,ISS)
regulation of systemic arterial blood pressure by renin-angiotensin  (IBA,IEA,ISO)
response to dexamethasone  (IEP)
response to hypoxia  (IEP)
response to laminar fluid shear stress  (IEP)
response to lipopolysaccharide  (IMP)
response to nutrient levels  (IEP)
response to thyroid hormone  (IEP)
response to xenobiotic stimulus  (IEP)
spermatogenesis  (IEA,ISO)
substance P catabolic process  (IEA,ISO,ISS)
vasoconstriction  (IMP)

Cellular Component

Molecular Pathway Annotations     Click to see Annotation Detail View
Phenotype Annotations     Click to see Annotation Detail View

Mammalian Phenotype
References

References - curated
# Reference Title Reference Citation
1. Protective effect of captopril against clozapine-induced myocarditis in rats: role of oxidative stress, proinflammatory cytokines and DNA damage. Abdel-Wahab BA, etal., Chem Biol Interact. 2014 Jun 5;216:43-52. doi: 10.1016/j.cbi.2014.03.012. Epub 2014 Apr 5.
2. Mechanisms of angiotensin converting enzyme inhibitor-induced IOP reduction in normotensive rats. Agarwal R, etal., Eur J Pharmacol. 2014 May 5;730:8-13. doi: 10.1016/j.ejphar.2014.02.021. Epub 2014 Feb 26.
3. Is serum angiotensin converting enzyme level a useful non-invasive marker for liver fibrosis in patients with chronic hepatitis C? Akar T, Rev Assoc Med Bras (1992). 2018 Mar;64(3):224-229. doi: 10.1590/1806-9282.64.03.224.
4. The effect of maternal administration of captopril on fetal development in rat. al-Shabanah OA, etal., Res Commun Chem Pathol Pharmacol. 1991 Aug;73(2):221-30.
5. Elevated serum angiotensin converting enzyme levels as a reflection of bone marrow renin-angiotensin system activation in multiple myeloma. Albayrak M, etal., J Renin Angiotensin Aldosterone Syst. 2012 Jun;13(2):259-64. doi: 10.1177/1470320312437070. Epub 2012 Feb 16.
6. Angiotensin-converting enzyme insertion/deletion gene polymorphism in patients with familial multiple cerebral cavernous malformations. Altas M, etal., J Clin Neurosci. 2010 Aug;17(8):1034-7. doi: 10.1016/j.jocn.2009.12.002. Epub 2010 May 21.
7. Effects of blockade of the renin-angiotensin and endothelin systems on experimental bronchiolitis obliterans. Antus B, etal., J Heart Lung Transplant. 2006 Nov;25(11):1324-9.
8. Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. Arafat HA, etal., J Am Coll Surg. 2007 May;204(5):996-1005; discussion 1005-6.
9. Angiotensin I-converting enzyme activity in puromycin aminonucleoside-nephrotic syndrome. Arevalo AE, etal., Clin Chim Acta. 1990 Nov 5;191(3):175-84.
10. Angiotensin-converting enzyme genotype predicts valve damage in acute rheumatic fever. Atalar E, etal., J Heart Valve Dis. 2003 Jan;12(1):7-10.
11. Polymorphism of angiotensin converting enzyme is associated with severe circulatory compromise in febrile neutropenic children with cancer. Bardi E, etal., Pediatr Blood Cancer. 2005 Aug;45(2):217-21.
12. ACE activity is modulated by the enzyme a-galactosidase A. Batista EC, etal., J Mol Med (Berl). 2011 Jan;89(1):65-74. doi: 10.1007/s00109-010-0686-2. Epub 2010 Oct 13.
13. Effects on cytokines and histology by treatment with the ACE inhibitor captopril and the antioxidant retinoic acid in the monocrotaline model of experimentally induced lung fibrosis. Baybutt RC, etal., Curr Pharm Des. 2007;13(13):1327-33.
14. The genetic association database. Becker KG, etal., Nat Genet. 2004 May;36(5):431-2.
15. No contribution of angiotensin-converting enzyme (ACE) gene variants to severe obesity: a model for comprehensive case/control and quantitative cladistic analysis of ACE in human diseases. Bell CG, etal., Eur J Hum Genet. 2007 Mar;15(3):320-7. Epub 2006 Dec 13.
16. Inhibiting angiotensin-converting enzyme promotes renal repair by limiting progenitor cell proliferation and restoring the glomerular architecture. Benigni A, etal., Am J Pathol. 2011 Aug;179(2):628-38. doi: 10.1016/j.ajpath.2011.04.003. Epub 2011 Jun 2.
17. Beneficial effect of TGFbeta antagonism in treating diabetic nephropathy depends on when treatment is started. Benigni A, etal., Nephron Exp Nephrol. 2006;104(4):e158-68. Epub 2006 Aug 10.
18. Separate metabolic pathways for Leu-enkephalin and Met-enkephalin-Arg(6)-Phe(7) degradation by rat striatal synaptosomal membranes. Benuck M, etal., Neurochem Int. 1982;4(5):389-96. doi: 10.1016/0197-0186(82)90081-x.
19. Elevated levels of circulating angiotensin converting enzyme in patients with hepatoportal sclerosis. Beyazit Y, etal., Dig Dis Sci. 2011 Jul;56(7):2160-5. doi: 10.1007/s10620-011-1580-7. Epub 2011 Feb 3.
20. Comparison of the incidence of imidapril and enalapril induced cough. Boonyapisit W and Tresukosol D, J Med Assoc Thai. 2010 Jan;93 Suppl 1:S48-53.
21. Involvement of renal ACE activity in proteinuria-associated renal damage in untreated and treated adriamycin nephrotic rats. Bos H, etal., J Renin Angiotensin Aldosterone Syst 2003 Jun;4(2):106-12.
22. Acute kidney injury in the rat causes cardiac remodelling and increases angiotensin-converting enzyme 2 expression. Burchill L, etal., Exp Physiol. 2008 May;93(5):622-30. doi: 10.1113/expphysiol.2007.040386. Epub 2008 Jan 25.
23. Myocardial infarction increases ACE2 expression in rat and humans. Burrell LM, etal., Eur Heart J 2005 Feb;26(4):369-75; discussion 322-4. Epub 2005 Jan 25.
24. Effects of maternal captopril treatment during late pregnancy on neonatal lung development in rats. Capelari DN, etal., Regul Pept. 2012 Aug 20;177(1-3):97-106. Epub 2012 May 12.
25. Enalapril and losartan restored blood pressure and vascular reactivity in intrauterine undernourished rats. Ceravolo GS, etal., Life Sci. 2007 Jan 30;80(8):782-7. Epub 2006 Nov 10.
26. Time course involvement of matrix metalloproteinases in the vascular alterations of renovascular hypertension. Ceron CS, etal., Matrix Biol. 2012 May;31(4):261-70. Epub 2012 Feb 10.
27. Angiotensin I-converting enzyme genotype influences arterial response to injury in normotensive rats. Challah M, etal., Arterioscler Thromb Vasc Biol. 1998 Feb;18(2):235-43.
28. Cardiac angiotensin converting enzyme overproduction indicates interstitial activation in renovascular hypertension. Challah M, etal., Cardiovasc Res. 1995 Aug;30(2):231-9.
29. Renin released from mast cells activated by circulating MCP-1 initiates the microvascular phase of the systemic inflammation of alveolar hypoxia. Chao J, etal., Am J Physiol Heart Circ Physiol. 2011 Dec;301(6):H2264-70. Epub 2011 Sep 30.
30. Release of angiotensin-(1-7) from the rat hindlimb: influence of angiotensin-converting enzyme inhibition. Chappell MC, etal., Hypertension. 2000 Jan;35(1 Pt 2):348-52.
31. Role of angiotensin II in retinal leukostasis in the diabetic rat. Chen P, etal., Exp Eye Res. 2006 Nov;83(5):1041-51. Epub 2006 Jul 5.
32. Effect of angiotensin I-converting enzyme inhibitory peptide from rice dregs protein on antihypertensive activity in spontaneously hypertensive rats. Chen Q, etal., Asia Pac J Clin Nutr. 2007;16 Suppl:281-5.
33. Role of angiotensin-converting enzyme gene polymorphisms in children with sepsis and septic shock. Cogulu O, etal., Pediatr Int. 2008 Aug;50(4):477-80. doi: 10.1111/j.1442-200X.2008.02583.x.
34. Sex-specific effects of low protein diet on in utero programming of renal G-protein coupled receptors. Cooke CL, etal., J Dev Orig Health Dis. 2014 Feb;5(1):36-44. doi: 10.1017/S2040174413000524.
35. Regulation of ACE gene expression and plasma levels during rat postnatal development. Costerousse O, etal., Am J Physiol. 1994 Nov;267(5 Pt 1):E745-53.
36. Angiotensin I-converting enzyme inhibition but not angiotensin II suppression alters angiotensin I-converting enzyme gene expression in vessels and epithelia. Costerousse O, etal., J Pharmacol Exp Ther. 1998 Mar;284(3):1180-7.
37. Age-related progressive renal fibrosis in rats and its prevention with ACE inhibitors and taurine. Cruz CI, etal., Am J Physiol Renal Physiol. 2000 Jan;278(1):F122-9.
38. Effects of E. coli endotoxin on rat plasma angiotensin converting enzyme activity in vitro and in vivo. Deitz DM, etal., Circ Shock. 1987;21(1):23-9.
39. COVID-19 infections are also affected by human ACE1 D/I polymorphism. Delanghe JR, etal., Clin Chem Lab Med. 2020 Jun 25;58(7):1125-1126. doi: 10.1515/cclm-2020-0425.
40. Pathways of bradykinin degradation in blood and plasma of normotensive and hypertensive rats. Dendorfer A, etal., Am J Physiol Heart Circ Physiol. 2001 May;280(5):H2182-8.
41. Locus for the inducible, but not a constitutive, nitric oxide synthase cosegregates with blood pressure in the Dahl salt-sensitive rat. Deng AY and Rapp JP, J Clin Invest 1995 May;95(5):2170-7
42. Cosegregation of blood pressure with angiotensin converting enzyme and atrial natriuretic peptide receptor genes using Dahl salt-sensitive rats. Deng Y and Rapp JP, Nat Genet 1992 Jul;1(4):267-72
43. Association study of ACE and eNOS single nucleotide polymorphisms with Henoch-Schonlein purpura nephritis. Di B, etal., Mol Med Rep. 2012 Nov;6(5):1171-7. doi: 10.3892/mmr.2012.1032. Epub 2012 Aug 10.
44. Effect of enalapril on exercise cardiopulmonary performance in chronic obstructive pulmonary disease: A pilot study. Di Marco F, etal., Pulm Pharmacol Ther. 2010 Jun;23(3):159-64. Epub 2010 Jan 22.
45. Correlations between ACE single nucleotide polymorphisms and prognosis of patients with septic shock. Dou XM, etal., Biosci Rep. 2017 Apr 28;37(2). pii: BSR20170145. doi: 10.1042/BSR20170145. Print 2017 Apr 30.
46. Effect of valsartan versus lisinopril on peritoneal sclerosis in rats. Duman S, etal., Int J Artif Organs. 2005 Feb;28(2):156-63.
47. Angiotensin 1-7 improves insulin sensitivity by increasing skeletal muscle glucose uptake in vivo. Echeverria-Rodriguez O, etal., Peptides. 2014 Jan;51:26-30. doi: 10.1016/j.peptides.2013.10.022. Epub 2013 Oct 31.
48. Effect of captopril treatment on recuperation from ischemia/reperfusion-induced acute renal injury. Efrati S, etal., Nephrol Dial Transplant. 2012 Jan;27(1):136-45. Epub 2011 Jun 16.
49. Angiotensin converting enzyme gene polymorphism in Turkish asthmatic patients. Eryuksel E, etal., J Asthma. 2009 May;46(4):335-8.
50. Influence of angiotensin-converting enzyme I/D gene polymorphism on clinical and histological correlates of chronic hepatitis C. Fabris C, etal., Hepatol Res. 2009 Aug;39(8):795-804. doi: 10.1111/j.1872-034X.2009.00518.x. Epub 2009 Apr 23.
51. Hepatotoxicity effect of short-term Bradykinin potentiating factor in cholestatic rats. Fahmy SR, etal., Toxicol Lett. 2019 Feb;301:73-78. doi: 10.1016/j.toxlet.2018.11.006. Epub 2018 Nov 17.
52. Angiotensin-converting enzyme DD genotype, angiotensin type 1 receptor CC genotype, and hyperhomocysteinemia increase first-trimester fetal-loss susceptibility. Fatini C, etal., Blood Coagul Fibrinolysis. 2000 Oct;11(7):657-62.
53. AGT and ACE genes influence classic mitral valve prolapse predisposition in Marfan patients. Fatini C, etal., Int J Cardiol. 2008 Jan 24;123(3):293-7. Epub 2007 Mar 26.
54. Effects of curcumin on angiotensin-converting enzyme gene expression, oxidative stress and anti-oxidant status in thioacetamide-induced hepatotoxicity. Fazal Y, etal., J Renin Angiotensin Aldosterone Syst. 2015 Dec;16(4):1046-51. doi: 10.1177/1470320314545777. Epub 2014 Aug 20.
55. The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Fendrich V, etal., Gut. 2010 May;59(5):630-7. Epub 2009 Nov 1.
56. Unexpected role of the human cytomegalovirus contribute to essential hypertension in the Kazakh Chinese population of Xinjiang. Feng Q, etal., Biosci Rep. 2018 Jun 27;38(3). pii: BSR20171522. doi: 10.1042/BSR20171522. Print 2018 Jun 29.
57. Genetic polymorphisms of the renin-angiotensin system in breast cancer patients. Fishchuk LE and Gorovenko NG, Exp Oncol. 2013 Jun;35(2):101-4.
58. Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis. Fogo A, etal., J Clin Invest. 1988 Jul;82(1):322-30.
59. Relationship between polymorphisms in the renin-angiotensin system and nephropathy in type 2 diabetic patients. Fradin S, etal., Diabetes Metab. 2002 Feb;28(1):27-32.
60. Angiotensin I-converting enzyme gene polymorphism is associated with myocardial infarction, but not with retinopathy or nephropathy, in NIDDM. Fujisawa T, etal., Diabetes Care. 1995 Jul;18(7):983-5.
61. Angiotensin converting enzyme activity is positively associated with IL-17a levels in patients with schizophrenia. Gadelha A, etal., Psychiatry Res. 2015 Oct 30;229(3):702-7. doi: 10.1016/j.psychres.2015.08.018. Epub 2015 Aug 12.
62. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
63. [Effect of carvedilol and perindopril on Ca(2+) pump activity and Ca(2+)-release channel density in myocardial sarcoplasmic reticulum in rats with chronic heart failure following myocardial infarction] Geng ZH, etal., Nan Fang Yi Ke Da Xue Xue Bao. 2009 Jul;29(7):1461-4.
64. Rat ISS GO annotations from GOA human gene data--August 2006 GOA data from the GO Consortium
65. Risk of venous thromboembolism associated with the insertion/deletion polymorphism in the angiotensin-converting enzyme gene. Gonzalez Ordonez AJ, etal., Blood Coagul Fibrinolysis. 2000 Jul;11(5):485-90.
66. Renin-angiotensin System Activation in Congenital Hepatic Fibrosis in the PCK Rat Model of Autosomal Recessive Polycystic Kidney Disease. Goto M, etal., J Pediatr Gastroenterol Nutr. 2010 Apr 14.
67. The renin-angiotensin system and hypertension in autosomal recessive polycystic kidney disease. Goto M, etal., Pediatr Nephrol. 2010 Dec;25(12):2449-57. doi: 10.1007/s00467-010-1621-z. Epub 2010 Aug 27.
68. Angiotensin-converting enzyme (ACE)-inhibition in cirrhosis. Pharmacokinetics and dynamics of the ACE-inhibitor cilazapril (Ro 31-2848). Gross V, etal., J Hepatol. 1993 Jan;17(1):40-7. doi: 10.1016/s0168-8278(05)80519-7.
69. Clinical course of sarcoidosis in dependence on HLA-DRB1 allele frequencies, inflammatory markers, and the presence of M. tuberculosis DNA fragments. Grosser M, etal., Sarcoidosis Vasc Diffuse Lung Dis. 2005 Mar;22(1):66-74.
70. Association between renin-angiotensin system gene polymorphism and recurrent wheezing in Chinese children: a 4-year follow-up study. Guo S, etal., J Int Med Res. 2009 Mar-Apr;37(2):351-8.
71. Effects of an angiotensin-converting enzyme inhibitor on the inflammatory response in in vivo and in vitro models. Hagiwara S, etal., Crit Care Med. 2009 Feb;37(2):626-33.
72. I/D ACE gene polymorphism in survival of leukemia patients -- hypothesis and pilot study. Hajek D, etal., Med Hypotheses. 2003 Jul;61(1):80-5.
73. [Increase of activity of angiotensin-converting enzyme in insulin-dependent diabetic patients with permanent microalbuminuria]. Hallab M, etal., Arch Mal Coeur Vaiss. 1992 Aug;85(8):1185-8.
74. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Harada E, etal., Circulation. 2001 Jul 10;104(2):137-9.
75. Heart mass and blood pressure have separate genetic determinants in the New Zealand genetically hypertensive (GH) rat. Harris EL, etal., J Hypertens 1995 Apr;13(4):397-404.
76. Long-term angiotensin-converting enzyme inhibitor perindopril therapy improves cerebral perfusion reserve in patients with previous minor stroke. Hatazawa J, etal., Stroke. 2004 Sep;35(9):2117-22. doi: 10.1161/01.STR.0000136034.86144.e9. Epub 2004 Jul 15.
77. Attenuation in rat brain nitric oxide synthase activity in the coarctation model of hypertension. Hegde LG, etal., Pharmacol Res. 1997 Aug;36(2):109-14.
78. Hemopressin is an inverse agonist of CB1 cannabinoid receptors. Heimann AS, etal., Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20588-93. doi: 10.1073/pnas.0706980105. Epub 2007 Dec 12.
79. Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of ACE and ACE2. Herath CB, etal., Am J Physiol Gastrointest Liver Physiol. 2009 Jul;297(1):G98-G106. Epub 2009 Apr 23.
80. The angiotensin I-converting enzyme (ACE) locus is strongly associated with age and duration of diabetes in patients with type I diabetes. Hibberd ML, etal., J Diabetes Complications. 1997 Jan-Feb;11(1):2-8.
81. Association of 3 gene polymorphisms with atopic diseases. Holla L, etal., J Allergy Clin Immunol. 1999 Apr;103(4):702-8.
82. Altered angiotensin-converting enzyme and its effects on the brain in a rat model of Alzheimer disease. Hou DR, etal., Chin Med J (Engl). 2008 Nov 20;121(22):2320-3.
83. ACE/ACE2 ratio and MMP-9 activity as potential biomarkers in tuberculous pleural effusions. Hsieh WY, etal., Int J Biol Sci. 2012;8(8):1197-205. doi: 10.7150/ijbs.5087. Epub 2012 Oct 17.
84. Maternal Resveratrol Therapy Protects Male Rat Offspring against Programmed Hypertension Induced by TCDD and Dexamethasone Exposures: Is It Relevant to Aryl Hydrocarbon Receptor? Hsu CN, etal., Int J Mol Sci. 2018 Aug 20;19(8):2459. doi: 10.3390/ijms19082459.
85. BML-111 equilibrated ACE-AngII-AT1R and ACE2-Ang-(1-7)-Mas axis to protect hepatic fibrosis in rats. Hu Q, etal., Prostaglandins Other Lipid Mediat. 2017 Jul;131:75-82. doi: 10.1016/j.prostaglandins.2017.08.008. Epub 2017 Aug 16.
86. Expression of angiotensin-converting enzyme 2 in CCL4-induced rat liver fibrosis. Huang Q, etal., Int J Mol Med. 2009 Jun;23(6):717-23. doi: 10.3892/ijmm_00000185.
87. [Expression and correlation of angiotensin-converting enzyme 2 in CCl4-induced rat liver fibrosis]. Huang Q, etal., Zhonghua Gan Zang Bing Za Zhi. 2013 Jan;21(1):47-52. doi: 10.3760/cma.j.issn.1007-3418.2013.01.013.
88. Effect of Antiviral Therapy on Serum Activity of Angiotensin Converting Enzyme in Patients with Chronic Hepatitis C. Husic-Selimovic A, etal., Med Arch. 2016 Apr;70(2):92-6. doi: 10.5455/medarh.2016.70.92-96. Epub 2016 Apr 1.
89. Carbonic adsorbent AST-120 retards progression of renal failure by additive effect with ACEI and protein restriction diet. Imai E, etal., Clin Exp Nephrol. 2003 Jun;7(2):113-9.
90. Significant association between insertion/deletion polymorphism of the angiotensin-convertig enzyme gene and ankylosing spondylitis. Inanir A, etal., Mol Vis. 2012;18:2107-13. Epub 2012 Jul 26.
91. Blockade of sensory abnormalities and kinin B(1) receptor expression by N-acetyl-L-cysteine and ramipril in a rat model of insulin resistance. Ismael MA, etal., Eur J Pharmacol. 2008 Jul 28;589(1-3):66-72. Epub 2008 May 16.
92. Genetic mapping of a gene causing hypertension in the stroke-prone spontaneously hypertensive rat. Jacob HJ, etal., Cell 1991 Oct 4;67(1):213-24
93. Ramipril mitigates radiation-induced impairment of neurogenesis in the rat dentate gyrus. Jenrow KA, etal., Radiat Oncol. 2010 Feb 1;5:6.
94. Chronic treatment with lisinopril decreases proliferative and apoptotic pathways in autosomal recessive polycystic kidney disease. Jia G, etal., Pediatr Nephrol. 2010 Jun;25(6):1139-46. Epub 2010 Mar 13.
95. Activation of the renin-angiotensin system in hyperoxia-induced lung fibrosis in neonatal rats. Jiang JS, etal., Neonatology. 2012;101(1):47-54. doi: 10.1159/000329451. Epub 2011 Jul 26.
96. Chronic infusion of enalaprilat into hypothalamic paraventricular nucleus attenuates angiotensin II-induced hypertension and cardiac hypertrophy by restoring neurotransmitters and cytokines. Kang YM, etal., Toxicol Appl Pharmacol. 2014 Feb 1;274(3):436-44. doi: 10.1016/j.taap.2013.12.001. Epub 2013 Dec 14.
97. Effect of lisinopril on renal tissue damage in unilateral ureteral obstruction in rats. Karabuga I, etal., Urol Res. 2012 Feb;40(1):27-34. doi: 10.1007/s00240-011-0393-7. Epub 2011 Jun 11.
98. Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure. Karram T, etal., Am J Physiol Heart Circ Physiol. 2005 Oct;289(4):H1351-8. Epub 2005 May 13.
99. Influence of angiotensin I-converting enzyme polymorphism on development of post-transplant erythrocytosis in renal graft recipients. Kedzierska K, etal., Clin Transplant. 2008 Mar-Apr;22(2):156-61. doi: 10.1111/j.1399-0012.2007.00760.x.
100. Association between polymorphisms of the angiotensin-converting enzyme and angiotensinogen genes and allergic rhinitis in a Korean population. Kim JJ, etal., Ann Otol Rhinol Laryngol. 2004 Apr;113(4):297-302.
101. Preventive effects of the angiotensin-converting enzyme inhibitor, captopril, on the development of azoxymethane-induced colonic preneoplastic lesions in diabetic and hypertensive rats. Kochi T, etal., Oncol Lett. 2014 Jul;8(1):223-229. Epub 2014 May 12.
102. Angiotensin blockade and the progression of renal damage in the spontaneously hypertensive rat. Kohara K, etal., Hypertension. 1993 Jun;21(6 Pt 2):975-9.
103. Angiotensin converting enzyme and genetic hypertension: cloning of rat cDNAs and characterization of the enzyme. Koike G, etal., Biochem Biophys Res Commun 1994 Jan 14;198(1):380-6.
104. Reciprocal interactions of obstructive sleep apnea and hypertension associated with ACE I/D polymorphism in males. Koyama RG, etal., Sleep Med. 2009 Dec;10(10):1107-11. Epub 2009 May 23.
105. Renal vasoconstriction in rats causes a decrease in capillary density and an increase in alkaline phosphatase expression in cardiac capillary nets. Koyama T and Taka A, Adv Exp Med Biol. 2010;662:83-8.
106. Genetic linkage of the ACE gene to plasma angiotensin-converting enzyme activity but not to blood pressure. A quantitative trait locus confers identical complex phenotypes in human and rat hypertension. Kreutz R, etal., Circulation 1995 Nov 1;92(9):2381-4.
107. Angiotensinogen and angiotensin-converting enzyme mRNA decrease and AT1 receptor mRNA and protein increase in epididymal fat tissue accompany age-induced elevation of adiposity and reductions in expression of GLUT4 and peroxisome proliferator-activated receptor (PPARgamma). Krskova K, etal., J Physiol Pharmacol. 2011 Aug;62(4):403-10.
108. Effects of angiotensin-converting enzyme gene polymorphism and serum vitamin D levels on ambulatory blood pressure measurement and left ventricular mass in Turkish hypertensive population. Kulah E, etal., Blood Press Monit. 2007 Aug;12(4):207-13.
109. Perinatal DDT Exposure Induces Hypertension and Cardiac Hypertrophy in Adult Mice. La Merrill MA, etal., Environ Health Perspect. 2016 Nov;124(11):1722-1727. doi: 10.1289/EHP164. Epub 2016 Jun 21.
110. Disease marker combination enhances patient characterization in the Finnish sarcoidosis patients. Lahtela E, etal., Respir Med. 2017 Nov;132:92-94. doi: 10.1016/j.rmed.2017.09.014. Epub 2017 Oct 3.
111. Association of angiotensin converting enzyme and angiotensin type 2 receptor gene polymorphisms with renal damage in posterior urethral valves. Laksmi NK, etal., J Pediatr Urol. 2010 Dec;6(6):560-6. Epub 2010 Feb 10.
112. Cellular and subcellular immunohistochemical localization of angiotensin-converting enzyme in the rat adrenal gland. Laliberte F, etal., Lab Invest. 1987 Apr;56(4):364-71.
113. Immunohistochemistry of angiotensin I-converting enzyme in rat eye structures involved in aqueous humor regulation. Laliberte MF, etal., Lab Invest. 1988 Aug;59(2):263-70.
114. Upregulation of a local renin-angiotensin system in the rat carotid body during chronic intermittent hypoxia. Lam SY, etal., Exp Physiol. 2014 Jan;99(1):220-31. doi: 10.1113/expphysiol.2013.074591. Epub 2013 Sep 13.
115. Regulation of the angiotensin-converting enzyme activity by a time-course hypoxia in the carotid body. Lam SY, etal., J Appl Physiol 2004 Feb;96(2):809-13. Epub 2003 Oct 3.
116. Mechanism of high glucose induced angiotensin II production in rat vascular smooth muscle cells. Lavrentyev EN, etal., Circ Res. 2007 Aug 31;101(5):455-64. Epub 2007 Jul 12.
117. Targeting the renin-angiotensin system: what's new? Leckie BJ Curr Med Chem Cardiovasc Hematol Agents. 2005 Jan;3(1):23-32.
118. [Serum angiotensin converting enzyme activity in sarcoidosis. A review of seventy cases]. Leclerc P, etal., Sem Hop. 1982 May 27;58(21):1291-4.
119. Enalapril inhibits nuclear factor-κB signaling in intestinal epithelial cells and peritoneal macrophages and attenuates experimental colitis in mice. Lee C, etal., Life Sci. 2014 Jan 24;95(1):29-39. doi: 10.1016/j.lfs.2013.11.005. Epub 2013 Nov 15.
120. Association of angiotensin-converting enzyme inhibitor therapy initiation with a reduction in hemoglobin levels in patients without renal failure. Leshem-Rubinow E, etal., Mayo Clin Proc. 2012 Dec;87(12):1189-95. doi: 10.1016/j.mayocp.2012.07.020. Epub 2012 Nov 7.
121. Angiotensin-Converting Enzyme N-Terminal Inactivation Alleviates Bleomycin-Induced Lung Injury. Li P, etal., Am J Pathol. 2010 Jul 22.
122. Balancing Effect of Biejiajian Oral Liquid () on ACE-Ang II-AT1R Axis and ACE2-Ang-(1-7)-Mas Axis in Rats with CCl4-Induced Hepatic Fibrosis. Li XY, etal., Chin J Integr Med. 2018 Nov;24(11):853-859. doi: 10.1007/s11655-017-2909-7. Epub 2018 Jan 15.
123. Association of angiotensin-converting enzyme gene 2350 G/A polymorphism with diabetic retinopathy in Chinese Han population. Liang S, etal., Mol Biol Rep. 2013 Jan;40(1):463-8. doi: 10.1007/s11033-012-2081-2. Epub 2012 Oct 13.
124. Inhibition of beta-myosin heavy chain gene expression in pressure overload rat heart by losartan and captopril. Ling Q, etal., Zhongguo Yao Li Xue Bao. 1997 Jan;18(1):63-6.
125. Sini decoction alleviates E. coli induced acute lung injury in mice via equilibrating ACE-AngII-AT1R and ACE2-Ang-(1-7)-Mas axis. Liu J, etal., Life Sci. 2018 Sep 1;208:139-148. doi: 10.1016/j.lfs.2018.07.013. Epub 2018 Jul 7.
126. Angiotensin-converting enzyme is a modifier of hypertensive end organ damage. Liu X, etal., J Biol Chem. 2009 Jun 5;284(23):15564-72. Epub 2009 Mar 23.
127. Podocyte repopulation contributes to regression of glomerular injury induced by ACE inhibition. Macconi D, etal., Am J Pathol. 2009 Mar;174(3):797-807. Epub 2009 Jan 22.
128. Renin-angiotensin-aldosterone system genes and nonarteritic anterior ischemic optic neuropathy. Markoula S, etal., Mol Vis. 2011;17:1254-60. Epub 2011 May 6.
129. Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Marre M, etal., Diabetes. 1994 Mar;43(3):384-8.
130. Detection of the association between a deletion polymorphism in the gene encoding angiotensin I-converting enzyme and advanced diabetic retinopathy. Matsumoto A, etal., Diabetes Res Clin Pract. 2000 Dec;50(3):195-202.
131. Upregulation of SERCA2a following short-term ACE inhibition (by enalaprilat) alters contractile performance and arrhythmogenicity of healthy myocardium in rat. Matus M, etal., Mol Cell Biochem. 2015 May;403(1-2):199-208. doi: 10.1007/s11010-015-2350-1. Epub 2015 Feb 8.
132. Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis protects against lung fibrosis by inhibiting the MAPK/NF-kappaB pathway. Meng Y, etal., Am J Respir Cell Mol Biol. 2014 Apr;50(4):723-36. doi: 10.1165/rcmb.2012-0451OC.
133. Germinal angiotensin I-converting enzyme is totally shed from the rodent sperm membrane during epididymal maturation. Metayer S, etal., Biol Reprod 2002 Dec;67(6):1763-7.
134. Angiotensin-converting enzyme in non-neoplastic kidney diseases. Metzger R, etal., Kidney Int. 1999 Oct;56(4):1442-54.
135. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
136. [Changing factors of the activity of angiotensin converting enzyme of renal brush border in rats]. Michel B, etal., Arch Mal Coeur Vaiss. 1991 Aug;84(8):1201-4.
137. Elevated serum levels of angiotensin-converting enzyme in patients with diabetic retinopathy. Migdalis IN, etal., South Med J. 1990 Apr;83(4):425-7.
138. Effect of an angiotensin II receptor blocker and two angiotensin converting enzyme inhibitors on transforming growth factor-beta (TGF-beta) and alpha-actomyosin (alpha SMA), important mediators of radiation-induced pneumopathy and lung fibrosis. Molteni A, etal., Curr Pharm Des. 2007;13(13):1307-16.
139. Renal ACE and ACE2 expression in early diabetic rats. Moon JY, etal., Nephron Exp Nephrol. 2008;110(1):e8-e16. Epub 2008 Aug 4.
140. The kallikrein-kinin system: current and future pharmacological targets. Moreau ME, etal., J Pharmacol Sci. 2005 Sep;99(1):6-38.
141. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Mortensen EM, etal., Respir Res. 2009 Jun 3;10:45.
142. Is angiotensin I-converting enzyme a "master" disease gene? Moskowitz DW, Diabetes Technol Ther. 2002;4(5):683-711. doi: 10.1089/152091502320798321.
143. Upregulation of Th1 cytokine profile in bronchoalveolar lavage fluid of patients with hypersensitivity pneumonitis. Mroz RM, etal., J Physiol Pharmacol. 2008 Dec;59 Suppl 6:499-505.
144. Antihypertensive medications and risk of community-acquired pneumonia. Mukamal KJ, etal., J Hypertens. 2010 Feb;28(2):401-5.
145. Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction. Murca TM, etal., Regul Pept. 2012 Aug 20;177(1-3):107-15. doi: 10.1016/j.regpep.2012.05.093. Epub 2012 May 14.
146. The impact of statins, ACE inhibitors and gastric acid suppressants on pneumonia mortality in a UK general practice population cohort. Myles PR, etal., Pharmacoepidemiol Drug Saf. 2009 Aug;18(8):697-703.
147. The impact of host's genetic susceptibility on Helicobacter pylori infection in children. Mărginean MO, etal., Medicine (Baltimore). 2017 Jul;96(30):e7612. doi: 10.1097/MD.0000000000007612.
148. Association of angiotensin converting enzyme gene insertion/deletion polymorphism with lung cancer in Turkey. Nacak M, etal., Cancer Genet Cytogenet. 2010 Apr 1;198(1):22-6.
149. Evidence for the involvement of NADPH oxidase in ischemia/reperfusion-induced gastric damage via angiotensin II. Nakagiri A, etal., J Physiol Pharmacol. 2010 Apr;61(2):171-9.
150. Effects of angiotensin inhibitors on renal injury and angiotensin receptor expression in early hypertensive nephrosclerosis. Nakaya H, etal., Hypertens Res. 1999 Nov;22(4):303-12.
151. Glomerular abundance of nephrin and podocin in experimental nephrotic syndrome: different effects of antiproteinuric therapies. Nakhoul F, etal., Am J Physiol Renal Physiol. 2005 Oct;289(4):F880-90. Epub 2005 Jun 7.
152. Tissue levels, tissue angiotensin converting enzyme inhibition and antihypertensive effect of the novel antihypertensive agent alacepril in renal hypertensive rats. Nambu K, etal., Arzneimittelforschung. 1986;36(1):47-51.
153. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
154. Changes in the renin angiotensin system during the development of colorectal cancer liver metastases. Neo JH, etal., BMC Cancer. 2010 Apr 10;10:134. doi: 10.1186/1471-2407-10-134.
155. Cardiac angiotensin II participates in coronary microvessel inflammation of unstable angina and strengthens the immunomediated component. Neri Serneri GG, etal., Circ Res. 2004 Jun 25;94(12):1630-7. Epub 2004 May 6.
156. Activation of cardiac renin-angiotensin system in unstable angina. Neri Serneri GG, etal., J Am Coll Cardiol. 2001 Jul;38(1):49-55.
157. ACE2 and ANG-(1-7) in the rat uterus during early and late gestation. Neves LA, etal., Am J Physiol Regul Integr Comp Physiol. 2008 Jan;294(1):R151-61. Epub 2007 Oct 31.
158. Serum angiotensin-converting enzyme level for evaluating significant fibrosis in chronic hepatitis B. Noguchi R, etal., World J Gastroenterol. 2017 Sep 28;23(36):6705-6714. doi: 10.3748/wjg.v23.i36.6705.
159. Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Ocaranza MP, etal., Hypertension. 2006 Oct;48(4):572-8. Epub 2006 Aug 14.
160. Isoproterenol and angiotensin I-converting enzyme in lung, left ventricle, and plasma during myocardial hypertrophy and fibrosis. Ocaranza MP, etal., J Cardiovasc Pharmacol. 2002 Aug;40(2):246-54.
161. Angiotensin I-converting enzyme gene polymorphism influences chronic hypertensive response in the rat Goldblatt model. Ocaranza MP, etal., J Hypertens 2002 Mar;20(3):413-20.
162. Effect of hypertension on angiotensin-(1-7) levels in rats with different angiotensin-I converting enzyme polymorphism. Ocaranza MP, etal., Life Sci. 2006 Feb 28;78(14):1535-42. Epub 2005 Oct 17.
163. Insertion/deletion polymorphism and serum activity of the angiotensin-converting enzyme in Turkish patients with obstructive sleep apnea syndrome. Ogus C, etal., Biochem Genet. 2010 Jun;48(5-6):516-23. Epub 2010 Feb 25.
164. Effects of an angiotensin-converting enzyme inhibitor-based regimen on pneumonia risk. Ohkubo T, etal., Am J Respir Crit Care Med. 2004 May 1;169(9):1041-5. Epub 2004 Feb 27.
165. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Oikawa T, etal., Kidney Int. 1997 Jan;51(1):164-72.
166. Lisinopril reduces cardiac hypertrophy and mortality in rats with aortocaval fistula. Oka T, etal., Eur J Pharmacol. 1993 Mar 30;234(1):55-60.
167. Antenatal glucocorticoid therapy suppresses angiotensin-converting enzyme activity in rats with nitrofen-induced congenital diaphragmatic hernia. Okoye BO, etal., J Pediatr Surg. 1998 Feb;33(2):286-91.
168. Mild but prolonged elevation of serum angiotensin converting enzyme (ACE) activity in alcoholics. Okuno F, etal., Alcohol. 1986 Nov-Dec;3(6):357-9. doi: 10.1016/0741-8329(86)90053-4.
169. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
170. The renin-angiotensin system genetic polymorphisms and rheumatic mitral valve disease. Ozisik K, etal., J Heart Valve Dis. 2004 Jan;13(1):33-7.
171. Angiotensin-converting enzyme gene polymorphism in Behcet's disease. Ozturk MA, etal., Clin Rheumatol. 2004 Apr;23(2):142-6. Epub 2004 Feb 24.
172. Angiotensin-converting enzyme I/D polymorphism in chronic obstructive pulmonary disease. Pabst S, etal., Eur J Med Res. 2009 Dec 7;14 Suppl 4:177-81.
173. Enalapril attenuates ischaemic brain oedema and protects the blood-brain barrier in rats via an anti-oxidant action. Panahpour H, etal., Clin Exp Pharmacol Physiol. 2014 Mar;41(3):220-6. doi: 10.1111/1440-1681.12210.
174. Polymorphism of the ACE Gene in dialysis patients: overexpression of DD genotype in type 2 diabetic end-stage renal failure patients. Park HC, etal., Yonsei Med J. 2005 Dec 31;46(6):779-87.
175. Effects of captopril and angiotensin II receptor blockers (AT1, AT2) on myocardial ischemia-reperfusion induced infarct size. Parlakpinar H, etal., Cytokine. 2011 Dec;56(3):688-94. Epub 2011 Oct 4.
176. Gene polymorphisms and febrile neutropenia in acute leukemia--no association with IL-4, CCR-5, IL-1RA, but the MBL-2, ACE, and TLR-4 are associated with the disease in Turkish patients: a preliminary study. Pehlivan M, etal., Genet Test Mol Biomarkers. 2014 Jul;18(7):474-81. doi: 10.1089/gtmb.2014.0004. Epub 2014 May 12.
177. Reduced circulating levels of angiotensin-(1--7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone control. Pignone A, etal., Ann Rheum Dis. 2007 Oct;66(10):1305-10. Epub 2007 Mar 14.
178. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
179. SMPDB Annotation Import Pipeline Pipeline to import SMPDB annotations from SMPDB into RGD
180. Angiotensin-converting enzyme inhibitor versus angiotensin II, AT1 receptor antagonist. Effects on smooth muscle cell migration and proliferation after balloon catheter injury. Prescott MF, etal., Am J Pathol. 1991 Dec;139(6):1291-6.
181. Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology. Qi Y, etal., Hypertension. 2013 Oct;62(4):746-52. doi: 10.1161/HYPERTENSIONAHA.113.01337. Epub 2013 Aug 19.
182. Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases Qiu QM, etal., Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2010 Apr;28(4):275-9.
183. Renin-angiotensin polymorphisms and QTc interval prolongation in end-stage renal disease. Raizada V, etal., Kidney Int. 2005 Sep;68(3):1186-9.
184. Atrial fibrosis in a chronic murine model of obstructive sleep apnea: mechanisms and prevention by mesenchymal stem cells. Ramos P, etal., Respir Res. 2014 Apr 28;15:54. doi: 10.1186/1465-9921-15-54.
185. [Angiotensin converting enzyme and left ventricular hypertrophy in uremic patients: correlation and therapeutic options]. Rasic S, etal., Acta Med Croatica. 2004;58(3):193-6.
186. GOA pipeline RGD automated data pipeline
187. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
188. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
189. Role of angiotensin II in ischemia/reperfusion-induced leukocyte-endothelium interactions in the colon. Riaz AA, etal., FASEB J. 2004 May;18(7):881-3. doi: 10.1096/fj.03-0502fje. Epub 2004 Mar 4.
190. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Rice GI, etal., Biochem J. 2004 Oct 1;383(Pt 1):45-51.
191. Suppression of angiotensin-converting enzyme expression and activity by shear stress. Rieder MJ, etal., Circ Res. 1997 Mar;80(3):312-9.
192. Novel natural peptide substrates for endopeptidase 24.15, neurolysin, and angiotensin-converting enzyme. Rioli V, etal., J Biol Chem. 2003 Mar 7;278(10):8547-55. doi: 10.1074/jbc.M212030200. Epub 2002 Dec 24.
193. Angiotensin-converting enzyme 2 (ACE2) and ACE activities display tissue-specific sensitivity to undernutrition-programmed hypertension in the adult rat. Riviere G, etal., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.
194. N-domain angiotensin-converting enzyme isoform expression in tissues of Wistar and spontaneously hypertensive rats. Ronchi FA, etal., J Hypertens. 2005 Oct;23(10):1869-78.
195. Inhibitory effect of alphaS1- and alphaS2-casein hydrolysates on angiotensin I-converting enzyme in human endothelial cells in vitro, rat aortic tissue ex vivo, and renovascular hypertensive rats in vivo. Rousseau-Ralliard D, etal., J Dairy Sci. 2010 Jul;93(7):2906-21. doi: 10.3168/jds.2010-3060.
196. No significant correlation between ACE Ins/Del genetic polymorphism and COVID-19 infection. Saadat M, Clin Chem Lab Med. 2020 Jun 25;58(7):1127-1128. doi: 10.1515/cclm-2020-0577.
197. Involvement of the renin-angiotensin system in the development of vascular damage in a rat model of arthritis: effect of angiotensin receptor blockers. Sakuta T, etal., Arthritis Rheum. 2010 May;62(5):1319-28.
198. Local corticosterone production and angiotensin-I converting enzyme shedding in a mouse model of intestinal inflammation. Salmenkari H, etal., World J Gastroenterol. 2015 Sep 21;21(35):10072-9. doi: 10.3748/wjg.v21.i35.10072.
199. An experimental model of encapsulating peritoneal sclerosis. Sawada T, etal., Perit Dial Int. 2009 Feb;29 Suppl 2:S49-50.
200. Effects of imatinib mesylate on renin-angiotensin system (RAS) activity during the clinical course of chronic myeloid leukaemia. Sayitoglu M, etal., J Int Med Res. 2009 Jul-Aug;37(4):1018-28.
201. Angiotensin-converting enzyme (ACE) gene polymorphisms and familial occurrence of sarcoidosis. Schürmann M, etal., J Intern Med. 2001 Jan;249(1):77-83. doi: 10.1046/j.1365-2796.2001.00776.x.
202. [To sanitize liv stock raising of helminthiases]. Sedov VA, Veterinariia. 1978 Dec;(12):10-2.
203. Association of ACE and MTHFR genetic polymorphisms with type 2 diabetes mellitus: Susceptibility and complications. Settin A, etal., J Renin Angiotensin Aldosterone Syst. 2014 Jan 22.
204. Angiotensin converting enzyme (ACE) gene expression in experimentally induced liver cirrhosis in rats. Shahid SM, etal., Pak J Pharm Sci. 2013 Sep;26(5):853-7.
205. Effect of caloric restriction on nitric oxide production, ACE activity, and blood pressure regulation in rats. Sharifi AM, etal., Acta Physiol Hung. 2008 Mar;95(1):55-63.
206. The ACE2/Ang-(1-7)/Mas Axis Confers Cardiopulmonary Protection against Lung Fibrosis and Pulmonary Hypertension. Shenoy V, etal., Am J Respir Crit Care Med. 2010 Jun 25.
207. Prevention of osteoporosis by angiotensin-converting enzyme inhibitor in spontaneous hypertensive rats. Shimizu H, etal., Hypertens Res. 2009 Sep;32(9):786-90. Epub 2009 Jul 10.
208. Preparation and antagonistic effect of ACE inhibitory peptide from cashew. Shu Y, etal., J Sci Food Agric. 2019 Dec;99(15):6822-6832. doi: 10.1002/jsfa.9967. Epub 2019 Sep 18.
209. Elevation of angiotensin-converting enzyme in granulomatous lymph nodes and serum in sarcoidosis: clinical and possible pathogenic significance. Silverstein E, etal., Ann N Y Acad Sci. 1976;278:498-513. doi: 10.1111/j.1749-6632.1976.tb47062.x.
210. Reduced severity of a mouse colitis model with angiotensin converting enzyme inhibition. Spencer AU, etal., Dig Dis Sci. 2007 Apr;52(4):1060-70. doi: 10.1007/s10620-006-9124-2. Epub 2007 Mar 7.
211. Angiotensin I-Converting Enzyme Insertion/Deletion Polymorphism and Increased Risk of Gall Bladder Cancer in Women. Srivastava K, etal., DNA Cell Biol. 2010 May 3.
212. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. Staessen JA, etal., J Hypertens. 1997 Dec;15(12 Pt 2):1579-92.
213. Statins and Angiotensin-Converting Enzyme Inhibitors are Associated with Reduced Mortality and Morbidity in Chronic Liver Disease. Stokkeland K, etal., Basic Clin Pharmacol Toxicol. 2018 Jan;122(1):104-110. doi: 10.1111/bcpt.12844. Epub 2017 Jul 30.
214. Differential ontogeny of rat brain peptidases: prenatal expression of enkephalin convertase and postnatal development of angiotensin-converting enzyme. Strittmatter SM, etal., Brain Res. 1986 Oct;394(2):207-15.
215. Influences of chymase and angiotensin I-converting enzyme gene polymorphisms on gastric cancer risks in Japan. Sugimoto M, etal., Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1929-34. doi: 10.1158/1055-9965.EPI-06-0339.
216. ACE-inhibitor suppresses the apoptosis induced by endoplasmic reticulum stress in renal tubular in experimental diabetic rats. Sun HL, etal., Exp Clin Endocrinol Diabetes. 2009 Jul;117(7):336-44. Epub 2009 Mar 19.
217. Evaluation of the roles of the Leiden V mutation and ACE I/D polymorphism in subtypes of ischaemic stroke. Szolnoki Z, etal., J Neurol. 2001 Sep;248(9):756-61.
218. Angiotensin converting enzyme genotype affects development and course of sarcoidosis in Asian Indians. Tahir M, etal., Sarcoidosis Vasc Diffuse Lung Dis. 2007 Sep;24(2):106-12.
219. Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Tarnow L, etal., Diabetes. 1995 May;44(5):489-94.
220. The restoration of kidney mitochondria function by inhibition of angiotensin-II production in rats with acute adriamycin-induced nephrotoxicity. Taskin E, etal., Ren Fail. 2014 May;36(4):606-12. doi: 10.3109/0886022X.2014.882737. Epub 2014 Feb 6.
221. Angiotensin-converting enzyme and angiotensin II type 1 receptor gene polymorphisms in children with subacute sclerosing panencephalitis. TaÅŸdemir N, etal., Am J Med Genet B Neuropsychiatr Genet. 2006 Jul 5;141B(5):445-8. doi: 10.1002/ajmg.b.30343.
222. Role of angiotensin converting enzyme in the vascular effects of an endopeptidase 24.15 inhibitor. Telford SE, etal., Br J Pharmacol. 1995 Mar;114(6):1185-92.
223. Prevention and intervention studies with telmisartan, ramipril and their combination in different rat stroke models. Thoene-Reineke C, etal., PLoS One. 2011;6(8):e23646. Epub 2011 Aug 25.
224. Central angiotensin converting enzyme facilitates memory impairment in intracerebroventricular streptozotocin treated rats. Tota S, etal., Behav Brain Res. 2012 Jan 1;226(1):317-30. Epub 2011 Aug 16.
225. Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor. Tseng CT, etal., J Virol. 2007 Feb;81(3):1162-73. Epub 2006 Nov 15.
226. Angiotensin-converting enzyme I/D polymorphism in Behcet's disease. Turgut S, etal., Med Princ Pract. 2005 Jul-Aug;14(4):213-6.
227. Angiotensin-converting enzyme gene polymorphism (insertion/deletion) and liver fibrosis in Turkish patients from the western Black Sea region, Turkey. Turhan NK, etal., Genet Mol Res. 2015 Dec 16;14(4):17079-90. doi: 10.4238/2015.December.16.8.
228. Polymorphisms of the angiotensin converting enzyme gene in early-onset and late-onset pre-eclampsia. Uma R, etal., J Matern Fetal Neonatal Med. 2010 Aug;23(8):874-9. doi: 10.3109/14767050903456667.
229. Upregulation of caveolin-1 expression is associated with structural modifications of endothelial cells in diabetic lung. Uyy E, etal., Microvasc Res. 2010 Mar;79(2):154-9. Epub 2010 Jan 6.
230. Angiotensin-converting enzyme (ACE) I/D corrected serum ACE activity and severity assessment of community-acquired pneumonia. van de Garde EM, etal., Clin Chem Lab Med. 2007;45(10):1326-31.
231. Genetic polymorphisms of the renin-angiotensin system and complications of insulin-dependent diabetes mellitus. van Ittersum FJ, etal., Nephrol Dial Transplant. 2000 Jul;15(7):1000-7.
232. Metabolic effects of low dose angiotensin converting enzyme inhibitor in dietary obesity in the rat. Velkoska E, etal., Nutr Metab Cardiovasc Dis. 2010 Jan;20(1):49-55. Epub 2009 Apr 9.
233. Angiotensin I converting enzyme activity in adriamycin induced nephrosis in rats. Venkatesan N, etal., Toxicology. 1993 Dec 31;85(2-3):137-48.
234. Malaria infection promotes a selective expression of kinin receptors in murine liver. Ventura PDS, etal., Malar J. 2019 Jun 24;18(1):213. doi: 10.1186/s12936-019-2846-3.
235. [Role of angiotensin II type 1 receptor in activation of nuclear factor-kappaB and activator protein-1 in lung of mice with acute lung injury]. Wang F, etal., Zhonghua Shao Shang Za Zhi. 2010 Apr;26(2):113-6.
236. Expression of ACE and ACE2 in patients with hypertensive nephrosclerosis. Wang G, etal., Kidney Blood Press Res. 2011;34(3):141-9. doi: 10.1159/000324521. Epub 2011 Feb 24.
237. Sustained inhibition of angiotensin I-converting enzyme (ACE) expression and long-term antihypertensive action by virally mediated delivery of ACE antisense cDNA. Wang H, etal., Circ Res. 1999 Oct 1;85(7):614-22.
238. A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Wang JL, etal., Kidney Int. 2000 Jun;57(6):2334-42.
239. [An experimental study of expression of angiotension converting enzyme 2 in myocardium and effect of telmisartan treatment in pressure-overloaded rats]. Wang LJ, etal., Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2008 Apr;20(4):218-22.
240. Inhibition of ACE activity contributes to the intestinal structural compensation in a massive intestinal resection rat model. Wang W, etal., Pediatr Surg Int. 2012 May;28(5):533-41. Epub 2012 Mar 24.
241. Antiproteinuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis. Wapstra FH, etal., Clin Sci (Lond). 1996 May;90(5):393-401.
242. ACE I/D polymorphism associated with abnormal atrial and atrioventricular conduction in lone atrial fibrillation and structural heart disease: implications for electrical remodeling. Watanabe H, etal., Heart Rhythm. 2009 Sep;6(9):1327-32. doi: 10.1016/j.hrthm.2009.05.014. Epub 2009 May 15.
243. Cardiac kallikrein-kinin system is upregulated in chronic volume overload and mediates an inflammatory induced collagen loss. Wei CC, etal., PLoS One. 2012;7(6):e40110. doi: 10.1371/journal.pone.0040110. Epub 2012 Jun 29.
244. Angiotensin-converting enzyme in sarcoid uveitis. Weinreb RN, etal., Invest Ophthalmol Vis Sci. 1979 Dec;18(12):1285-7.
245. Hormonal determinants of sodium excretion in rats with experimental high-output heart failure. Winaver J, etal., Am J Physiol. 1988 May;254(5 Pt 2):R776-84.
246. Ventilator-induced inflammatory response in lipopolysaccharide-exposed rat lung is mediated by angiotensin-converting enzyme. Wosten-van Asperen RM, etal., Am J Pathol. 2010 May;176(5):2219-27. Epub 2010 Mar 19.
247. Renin-angiotensin system gene polymorphisms and diastolic heart failure. Wu CK, etal., Eur J Clin Invest. 2008 Nov;38(11):789-97. doi: 10.1111/j.1365-2362.2008.02017.x.
248. Demonstrating the pharmacogenetic effects of angiotensin-converting enzyme inhibitors on long-term prognosis of diastolic heart failure. Wu CK, etal., Pharmacogenomics J. 2010 Feb;10(1):46-53. doi: 10.1038/tpj.2009.39. Epub 2009 Sep 15.
249. Inhibition of AAA in a rat model by treatment with ACEI perindopril. Xiong F, etal., J Surg Res. 2014 Jun 1;189(1):166-73. doi: 10.1016/j.jss.2014.01.057. Epub 2014 Feb 5.
250. Lack of association of polymorphisms of the angiotensin converting enzyme and angiotensinogen genes with nonfamilial hypertrophic or dilated cardiomyopathy. Yamada Y, etal., Am J Hypertens. 1997 Aug;10(8):921-8.
251. Beneficial effects of beta-conglycinin on renal function and nephrin expression in early streptozotocin-induced diabetic nephropathy rats. Yang HY, etal., Br J Nutr. 2014 Jan 14;111(1):78-85. doi: 10.1017/S0007114513001876. Epub 2013 Jun 27.
252. Angiotensin-converting enzyme gene polymorphism is associated with anemia in non small-cell lung cancer. Yaren A, etal., Exp Biol Med (Maywood). 2008 Jan;233(1):32-7.
253. Angiotensin-converting enzyme inhibition promotes coronary angiogenesis in the failing heart of Dahl salt-sensitive hypertensive rats. Yazawa H, etal., J Card Fail. 2011 Dec;17(12):1041-50. Epub 2011 Oct 17.
254. Epistatic interaction between variations in the angiotensin I converting enzyme and angiotensin II type 1 receptor genes in relation to extent of coronary atherosclerosis. Ye S, etal., Heart. 2003 Oct;89(10):1195-9.
255. The role of IL-4 gene 70 bp VNTR and ACE gene I/D variants in Familial Mediterranean fever. Yigit S, etal., Cytokine. 2014 May;67(1):1-6. doi: 10.1016/j.cyto.2014.01.007. Epub 2014 Feb 22.
256. Interdependent effect of angiotensin-converting enzyme and platelet-activating factor acetylhydrolase gene polymorphisms on the progression of immunoglobulin A nephropathy. Yoon HJ, etal., Clin Genet. 2002 Aug;62(2):128-34.
257. AT1 receptor blocker added to ACE inhibitor provides benefits at advanced stage of hypertensive diastolic heart failure. Yoshida J, etal., Hypertension. 2004 Mar;43(3):686-91. doi: 10.1161/01.HYP.0000118017.02160.fa. Epub 2004 Feb 2.
258. Some characteristics of a peptidyl dipeptidase (kininase II) from rat CSF: differential effects of NaCl on the sequential degradation steps of bradykinin. Yoshida T and Nosaka S, J Neurochem. 1990 Dec;55(6):1861-9.
259. Interferon augments the anti-fibrotic activity of an angiotensin-converting enzyme inhibitor in patients with refractory chronic hepatitis C. Yoshiji H, etal., World J Gastroenterol. 2006 Nov 14;12(42):6786-91. doi: 10.3748/wjg.v12.i42.6786.
260. Role of rat intestinal brush-border membrane angiotensin-converting enzyme in dietary protein digestion. Yoshioka M, etal., Am J Physiol. 1987 Dec;253(6 Pt 1):G781-6.
261. Deletion polymorphism of the angiotensin converting enzyme gene predicts persistent proteinuria in Henoch-Schonlein purpura nephritis. Yoshioka T, etal., Arch Dis Child. 1998 Nov;79(5):394-9.
262. Polski tygodnik lekarski (Warsaw, Poland : 1960) Zderkiewicz E Pol Tyg Lek 1978 Jul 17;33(29):1157-9.
263. Relationship between polymorphism of angiotensin-converting enzyme gene insertion/deletion and risk of hepatocellular carcinoma in a Chinese Dai population. Zha Y, etal., J Renin Angiotensin Aldosterone Syst. 2015 Sep;16(3):695-9. doi: 10.1177/1470320314539829. Epub 2014 Sep 10.
264. Interaction of angiotensin I-converting enzyme insertion-deletion polymorphism and daily salt intake influences hypertension in Japanese men. Zhang L, etal., Hypertens Res. 2006 Oct;29(10):751-8.
265. Association of angiotensin-converting enzyme gene I/D and CYP11B2 gene -344T/C polymorphisms with lone atrial fibrillation and its recurrence after catheter ablation. Zhang XL, etal., Exp Ther Med. 2012 Oct;4(4):741-747. Epub 2012 Jul 31.
266. Angiotensin-converting enzyme gene insertion/deletion polymorphism in children with Henoch-Schonlein purpua nephritis. Zhou J, etal., J Huazhong Univ Sci Technolog Med Sci. 2004;24(2):158-61.
Additional References at PubMed
PMID:174834   PMID:1298871   PMID:1320019   PMID:1668266   PMID:1848554   PMID:1851160   PMID:2846041   PMID:2849100   PMID:2983326   PMID:4322742   PMID:6208535   PMID:7683654  
PMID:7876104   PMID:9231832   PMID:9449382   PMID:10406820   PMID:11076943   PMID:11303049   PMID:11702851   PMID:12193663   PMID:12477932   PMID:12540854   PMID:12963491   PMID:14527934  
PMID:14615289   PMID:14693687   PMID:14872008   PMID:15047629   PMID:15194348   PMID:15326289   PMID:15475532   PMID:15489334   PMID:15531746   PMID:15869764   PMID:15932931   PMID:15961527  
PMID:15992826   PMID:16009784   PMID:16027241   PMID:16116425   PMID:16186248   PMID:16230508   PMID:16325859   PMID:16434838   PMID:16502470   PMID:16585392   PMID:17077303   PMID:17082641  
PMID:17135368   PMID:17487824   PMID:17785632   PMID:17898118   PMID:17903697   PMID:18174884   PMID:18495113   PMID:18957386   PMID:19012043   PMID:19056867   PMID:19255705   PMID:19419949  
PMID:19472100   PMID:19733634   PMID:19773553   PMID:20011602   PMID:20022959   PMID:20051229   PMID:20116413   PMID:20570682   PMID:20888351   PMID:21053061   PMID:21082674   PMID:21167844  
PMID:21495912   PMID:21602471   PMID:21720771   PMID:21788250   PMID:21959517   PMID:22191573   PMID:22311897   PMID:22378820   PMID:22498331   PMID:23132538   PMID:23365412   PMID:23376485  
PMID:23533145   PMID:23535237   PMID:23603844   PMID:23661144   PMID:23706365   PMID:23733546   PMID:23749777   PMID:23975725   PMID:24126381   PMID:24781988   PMID:25017399   PMID:25031298  
PMID:25194129   PMID:25205218   PMID:25217176   PMID:25401104   PMID:25766467   PMID:25768373   PMID:26010093   PMID:26371174   PMID:26400542   PMID:26697495   PMID:27465904   PMID:27710705  
PMID:27923787   PMID:27995995   PMID:28003214   PMID:28536140   PMID:29360395   PMID:30806143   PMID:31346990   PMID:35969203   PMID:37052403  


Genomics

Comparative Map Data
Ace
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr81091,410,129 - 91,430,246 (+)NCBIGRCr8
mRatBN7.21090,910,316 - 90,930,437 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1090,910,316 - 90,931,131 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1095,964,627 - 95,984,783 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01095,427,801 - 95,447,951 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01090,839,016 - 90,859,102 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01094,170,766 - 94,213,831 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1094,170,766 - 94,187,822 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01093,922,062 - 93,965,127 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41095,361,338 - 95,381,455 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
Celera1089,588,544 - 89,608,666 (+)NCBICelera
Cytogenetic Map10q32.1NCBI
ACE
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh381763,477,061 - 63,498,373 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl1763,477,061 - 63,498,380 (+)EnsemblGRCh38hg38GRCh38
GRCh371761,554,422 - 61,575,734 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 361758,908,166 - 58,928,711 (+)NCBINCBI36Build 36hg18NCBI36
Build 341758,915,908 - 58,952,935NCBI
Celera1755,942,475 - 55,963,778 (+)NCBICelera
Cytogenetic Map17q23.3NCBI
HuRef1756,922,781 - 56,944,100 (+)NCBIHuRef
CHM1_11761,618,550 - 61,639,869 (+)NCBICHM1_1
T2T-CHM13v2.01764,347,269 - 64,368,872 (+)NCBIT2T-CHM13v2.0
Ace
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm3911105,858,774 - 105,880,790 (+)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl11105,858,771 - 105,880,790 (+)EnsemblGRCm39 Ensembl
GRCm3811105,967,948 - 105,989,964 (+)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl11105,967,945 - 105,989,964 (+)EnsemblGRCm38mm10GRCm38
MGSCv3711105,829,261 - 105,851,259 (+)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv3611105,784,049 - 105,805,350 (+)NCBIMGSCv36mm8
Celera11117,699,475 - 117,721,491 (+)NCBICelera
Cytogenetic Map11E1NCBI
cM Map1168.84NCBI
ACE
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
NHGRI_mPanPan1-v21979,648,057 - 79,669,151 (+)NCBINHGRI_mPanPan1-v2
NHGRI_mPanPan11784,465,633 - 84,486,649 (+)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v01757,556,294 - 57,577,294 (+)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.11762,710,398 - 62,724,018 (+)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl1762,702,341 - 62,733,853 (+)Ensemblpanpan1.1panPan2
ACE
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
CanFam3.1911,497,182 - 11,516,362 (+)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl911,497,182 - 11,516,358 (+)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha912,457,866 - 12,477,045 (+)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.0913,160,704 - 13,179,888 (+)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl913,160,704 - 13,200,795 (+)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.1912,105,344 - 12,124,523 (+)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.0915,407,255 - 15,426,429 (-)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.0915,410,134 - 15,429,354 (-)NCBIUU_Cfam_GSD_1.0
LOC101968921
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HiC_Itri_2NW_02440560215,017,159 - 15,036,742 (-)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_0049365414,157,393 - 4,178,177 (+)EnsemblSpeTri2.0SpeTri2.0 Ensembl
SpeTri2.0NW_0049365414,157,847 - 4,178,156 (+)NCBISpeTri2.0SpeTri2.0SpeTri2.0
ACE
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 Ensembl1215,394,487 - 15,414,703 (-)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.11215,394,487 - 15,414,609 (-)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.21215,381,362 - 15,401,171 (-)NCBISscrofa10.2Sscrofa10.2susScr3
Ace
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HetGla_female_1.0 EnsemblNW_004624849998,277 - 1,019,521 (+)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_004624849998,262 - 1,019,305 (+)NCBIHetGla_female_1.0HetGla 1.0hetGla2

Variants

.
Variants in Ace
84 total Variants

QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
2312662Slep8Serum leptin concentration QTL 80.05blood leptin amount (VT:0005667)serum leptin level (CMO:0000780)1057134272102134272Rat
2312668Scl65Serum cholesterol level QTL 650.001blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)1057134272102134272Rat
2312672Insul15Insulin level QTL 150.01blood insulin amount (VT:0001560)serum insulin level (CMO:0000358)1057134272102134272Rat
2306970Anxrr22Anxiety related response QTL 225.95fear/anxiety-related behavior trait (VT:1000241)number of periods of voluntary immobility (CMO:0001045)106134527698211570Rat
2316949Gluco60Glucose level QTL 603.7blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)1014487011107057807Rat
2317029Aia19Adjuvant induced arthritis QTL 192.98joint integrity trait (VT:0010548)left rear ankle joint diameter (CMO:0002149)1066978955107211142Rat
2317039Aia6Adjuvant induced arthritis QTL 64.31joint integrity trait (VT:0010548)right rear ankle joint diameter (CMO:0002150)1066978955107211142Rat
1298069Bp168Blood pressure QTL 1685.5blood pressure trait (VT:0000183)systolic blood pressure (CMO:0000004)102652195798003205Rat
1298078Stresp5Stress response QTL 52.990.00025blood corticosterone amount (VT:0005345)plasma corticosterone level (CMO:0001173)1042045676104670812Rat
2317754Glom25Glomerulus QTL 253.5urine protein amount (VT:0005160)urine protein level (CMO:0000591)1082685200107211142Rat
4889948Bss91Bone structure and strength QTL 914tibia area (VT:1000281)tibia midshaft total cross-sectional area (CMO:0001715)108256485692369470Rat
6893336Cm75Cardiac mass QTL 750.10.87heart mass (VT:0007028)heart weight to body weight ratio (CMO:0000074)106134527699703528Rat
6893357Bw102Body weight QTL 1020.50.36body mass (VT:0001259)body weight (CMO:0000012)1080515287101325465Rat
6893366Bw106Body weight QTL 1060.30.47body mass (VT:0001259)body weight (CMO:0000012)1070199100107211142Rat
631269Cia22Collagen induced arthritis QTL 228.9joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1040035094104060283Rat
631270Cia23Collagen induced arthritis QTL 233.9joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1040035094104060283Rat
631530Tls3T-lymphoma susceptibility QTL 300.0001thymus integrity trait (VT:0010555)percentage of study population developing T-cell lymphomas during a period of time (CMO:0001911)105177461295600334Rat
631538Oia5Oil induced arthritis QTL 5joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1087055121107211142Rat
631542Bp82Blood pressure QTL 826.8arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)102652195798952741Rat
631547Bp87Blood pressure QTL 874.5arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)104736947092369470Rat
631555Bp134Blood pressure QTL 1340.001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)108051528791230079Rat
634320Niddm49Non-insulin dependent diabetes mellitus QTL 494.41blood glucose amount (VT:0000188)plasma glucose level (CMO:0000042)1088539139107211142Rat
1300107Rf18Renal function QTL 183.41urine output (VT:0003620)timed urine volume (CMO:0000260)107877551698279596Rat
1300137Bp186Blood pressure QTL 1863.57arterial blood pressure trait (VT:2000000)blood pressure time series experimental set point of the baroreceptor response (CMO:0002593)1090627439107057807Rat
1302404Cia27Collagen induced arthritis QTL 272.60.0045joint integrity trait (VT:0010548)experimental arthritis severity measurement (CMO:0001459)1076452683107211142Rat
1354608Cm33Cardiac mass QTL 332.8heart left ventricle mass (VT:0007031)heart left ventricle wet weight (CMO:0000071)105480929299809292Rat
1359017Hrtrt21Heart rate QTL 212.4heart pumping trait (VT:2000009)heart rate (CMO:0000002)105177294096772940Rat
1558643Cm44Cardiac mass QTL 444.80.0000368heart mass (VT:0007028)heart wet weight (CMO:0000069)106134527699703528Rat
1549846Scl47Serum cholesterol level QTL 473.6blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)105057470795574707Rat
1554317Bmd4Bone mineral density QTL 49.40.0001lumbar vertebra mineral mass (VT:0010511)volumetric bone mineral density (CMO:0001553)101981604299406971Rat
1358188Ept9Estrogen-induced pituitary tumorigenesis QTL 93.9pituitary gland mass (VT:0010496)pituitary gland wet weight (CMO:0000853)107345313696120911Rat
1549831Bss6Bone structure and strength QTL 64lumbar vertebra strength trait (VT:0010574)vertebra ultimate force (CMO:0001678)1057576521102576521Rat
1579919Bp281Blood pressure QTL 2810.01arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)107437208494965338Rat
1579915Bp280Blood pressure QTL 2800.001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1090404397107211142Rat
1576308Schws1Schwannoma susceptibility QTL 10.0041nervous system integrity trait (VT:0010566)percentage of study population developing trigeminal nerve neurilemmomas during a period of time (CMO:0002017)1040035094102359817Rat
61354Pia10Pristane induced arthritis QTL 100.01joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1023444813104060283Rat
61363Oia3Oil induced arthritis QTL 30.001joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1087307617107211142Rat
61396Bp9Blood pressure QTL 94.80.0001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1068420376107211142Rat
61427Cia16Collagen induced arthritis QTL 163.2joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)10635789696121100Rat
2292438Bp311Blood pressure QTL 311arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1076246085107211142Rat
2292617Ept18Estrogen-induced pituitary tumorigenesis QTL 183.9pituitary gland mass (VT:0010496)pituitary gland wet weight (CMO:0000853)107345313696120911Rat
631267Cia20Collagen induced arthritis QTL 203.2joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1023444813104060283Rat
631268Cia21Collagen induced arthritis QTL 213.1joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1014487011104060283Rat
61449Ciaa2CIA Autoantibody QTL 27.1blood autoantibody amount (VT:0003725)calculated serum anti-type 2 collagen antibody titer (CMO:0001279)1063221094107211142Rat
70164Bw21Body weight QTL 214.360.00005body mass (VT:0001259)body weight (CMO:0000012)105379749498952626Rat
70171Cari1Carrageenan-induced inflammation QTL 14.90.0005hypodermis integrity trait (VT:0010550)inflammatory exudate volume (CMO:0001429)1053797385107211142Rat
61325Aia5Adjuvant induced arthritis QTL 50.01joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1023444813104060283Rat
2298548Neuinf7Neuroinflammation QTL 73.4nervous system integrity trait (VT:0010566)spinal cord RT1-B protein level (CMO:0002132)1072224939107211142Rat
2300218Hpcl2Hepatic cholesterol level QTL 2liver cholesterol amount (VT:0010498)liver cholesterol level (CMO:0001597)104502965095600334Rat
2306792Ean4Experimental allergic neuritis QTL 44nervous system integrity trait (VT:0010566)IFNG-secreting splenocyte count (CMO:0002122)108402232193995963Rat
2306793Ean5Experimental allergic neuritis QTL 54.7nervous system integrity trait (VT:0010566)IFNG-secreting splenocyte count (CMO:0002122)107255241693995749Rat
724530Bp149Blood pressure QTL 1490.0001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1090627439107211142Rat
2313856Bp342Blood pressure QTL 3424.40.0001life span trait (VT:0005372)age at time of death (CMO:0001193)108730761796121100Rat
2313105Bss79Bone structure and strength QTL 791.80.0001tibia size trait (VT:0100001)tibia midshaft cross-sectional area (CMO:0001717)1062057807107057807Rat
1642980Bp300Blood pressure QTL 300arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1068383129107211142Rat
1331791Cm31Cardiac mass QTL 313.84606heart mass (VT:0007028)heart wet weight (CMO:0000069)1029299504107211142Rat
1357344Bp249Blood pressure QTL 2490.0001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)106674365598003205Rat
70193Mcs7Mammary carcinoma susceptibility QTL 72.38mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)1072224939107211142Rat
4889492Pancm2Pancreatic morphology QTL 23.2pancreatic beta cell morphology trait (VT:0005217)ratio of insulin-positive cell area to total area of splenic region of pancreas (CMO:0001814)1076748906107211142Rat
1558652Bw57Body weight QTL 574.20.0008body mass (VT:0001259)body weight (CMO:0000012)108932701790930437Rat
12880385Cm108Cardiac mass QTL 1080.001heart left ventricle mass (VT:0007031)heart left ventricle weight to body weight ratio (CMO:0000530)90404397107211142Rat
2301398Kidm38Kidney mass QTL 380.002kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)108400727295933025Rat
2303589Bw87Body weight QTL 872body mass (VT:0001259)body weight (CMO:0000012)1081285008107211142Rat
10450498Bp384Blood pressure QTL 3840.002arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1067750049107211142Rat
2300172Bmd57Bone mineral density QTL 579.80.0001femur mineral mass (VT:0010011)volumetric bone mineral density (CMO:0001553)1069738412107211142Rat
12880396Am13Aortic mass QTL 130.001aorta mass (VT:0002845)aorta weight to aorta length to body weight ratio (CMO:0002722)1090404397107211142Rat
2303118Mamtr7Mammary tumor resistance QTL 70.003mammary gland integrity trait (VT:0010552)mammary tumor growth rate (CMO:0000344)109658275104670812Rat
2293646Bss25Bone structure and strength QTL 2510.960.0001femur morphology trait (VT:0000559)femur cross-sectional area (CMO:0001661)1069738412107211142Rat
2293663Bss33Bone structure and strength QTL 339.340.0001femur strength trait (VT:0010010)femur midshaft polar moment of inertia (CMO:0001669)1069738412107211142Rat
1600367Mcs15Mammary carcinoma susceptibility QTL 154.5mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)1085565469103884409Rat
12880395Cm109Cardiac mass QTL 1090.001heart right ventricle mass (VT:0007033)heart right ventricle weight to body weight ratio (CMO:0000914)1090404397107211142Rat
10450495Bp383Blood pressure QTL 3830.002arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)107624608594965338Rat
61387Bp1Blood pressure QTL 15.1arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1051770177107211142Rat
61387Bp1Blood pressure QTL 15.1arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)1051770177107211142Rat
631535Cm51Cardiac mass QTL 513heart mass (VT:0007028)calculated heart weight (CMO:0000073)105178628291669536Rat
70364Bp72Blood pressure QTL 72arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)105112110096121100Rat
12880055Am11Aortic mass QTL 110.004aorta mass (VT:0002845)aorta weight to aorta length to body weight ratio (CMO:0002722)108400727295933025Rat
2293698Bss43Bone structure and strength QTL 435.330.0001lumbar vertebra size trait (VT:0010518)lumbar vertebra cross-sectional area (CMO:0001689)1059209888104209888Rat
2313103Bss80Bone structure and strength QTL 8020.0001tibia strength trait (VT:1000284)tibia midshaft endosteal cross-sectional area (CMO:0001716)1062057807107057807Rat
12880384Cm107Cardiac mass QTL 1070.001heart mass (VT:0007028)heart wet weight to body weight ratio (CMO:0002408)90404397107211142Rat
12880398Kidm67Kidney mass QTL 670.001kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)1090404397107211142Rat

Markers in Region
D10Mit1  
Rat AssemblyChrPosition (strand)SourceJBrowse
Rnor_5.01093,929,621 - 93,929,812NCBIRnor5.0
RGSC_v3.41095,368,898 - 95,369,088RGDRGSC3.4
RGSC_v3.11095,383,268 - 95,383,458RGD
SHRSP x BN Map1068.71RGD
SHRSP x BN Map1068.71UniSTS
FHH x ACI Map1075.81RGD
Cytogenetic Map10q32.1UniSTS
D10Wox18  
Rat AssemblyChrPosition (strand)SourceJBrowse
Rnor_6.01094,178,338 - 94,178,506NCBIRnor6.0
Rnor_5.01093,929,634 - 93,929,802UniSTSRnor5.0
RGSC_v3.41095,368,909 - 95,369,078RGDRGSC3.4
RGSC_v3.41095,368,910 - 95,369,078UniSTSRGSC3.4
RGSC_v3.11095,383,279 - 95,383,448RGD
Celera1089,596,121 - 89,596,289UniSTS
RH 3.4 Map10978.1UniSTS
RH 3.4 Map10978.1RGD
RH 2.0 Map101075.9RGD
Cytogenetic Map10q32.1UniSTS
RH94768  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21090,930,321 - 90,930,437 (+)MAPPERmRatBN7.2
Rnor_6.01094,084,710 - 94,084,825NCBIRnor6.0
Rnor_5.01093,840,108 - 93,840,223UniSTSRnor5.0
RGSC_v3.41095,381,340 - 95,381,455UniSTSRGSC3.4
Celera1089,608,551 - 89,608,666UniSTS
Cytogenetic Map10q32.1UniSTS


Related Rat Strains
The following Strains have been annotated to Ace
LOU.BN-(D10Mgh1-D10Mgh14)/Ins     SD-Tg(Ren2)27     SS.MNS-(D10M11Mit119-D10Mit11)/Jr    


Genetic Models
This gene Ace is modified in the following models/strains:
SS-Aceem1Mcwi     SS-Aceem2Mcwi    


Expression


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

circulatory system endocrine system exocrine system hepatobiliary system nervous system renal system reproductive system
High
Medium 23 10 15
Low 30 2 2 2 40 14 15
Below cutoff 2 20 20 20

Sequence


Reference Sequences
RefSeq Acc Id: ENSRNOT00000010627   ⟹   ENSRNOP00000010627
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1090,910,316 - 90,930,476 (+)Ensembl
Rnor_6.0 Ensembl1094,170,766 - 94,187,822 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000092961
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1090,917,450 - 90,930,476 (+)Ensembl
Rnor_6.0 Ensembl1094,177,889 - 94,187,822 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000119881   ⟹   ENSRNOP00000084667
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1090,910,316 - 90,931,131 (+)Ensembl
RefSeq Acc Id: NM_012544   ⟹   NP_036676
RefSeq Status: PROVISIONAL
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr81091,410,129 - 91,430,246 (+)NCBI
mRatBN7.21090,910,316 - 90,930,437 (+)NCBI
Rnor_6.01094,170,766 - 94,213,831 (+)NCBI
Rnor_5.01093,922,062 - 93,965,127 (+)NCBI
RGSC_v3.41095,361,338 - 95,381,455 (+)RGD
Celera1089,588,544 - 89,608,666 (+)RGD
Sequence:
Reference Protein Sequences
RefSeq Acc Id: NP_036676   ⟸   NM_012544
- Peptide Label: precursor
- UniProtKB: Q9EQM9 (UniProtKB/Swiss-Prot),   Q8CFN1 (UniProtKB/Swiss-Prot),   Q7TMC6 (UniProtKB/Swiss-Prot),   P47820 (UniProtKB/Swiss-Prot),   A6HJZ3 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: ENSRNOP00000010627   ⟸   ENSRNOT00000010627
RefSeq Acc Id: ENSRNOP00000084667   ⟸   ENSRNOT00000119881
Protein Domains
Peptidase M2

Protein Structures
Name Modeler Protein Id AA Range Protein Structure Video
AF-P47820-F1-model_v2 AlphaFold P47820 1-1313 view protein structure  
ACE N-Terminal pdb 2c6f P47820 36-636 view protein structure  
ACE C-Terminal pdb 108a P47820 637-1238 view protein structure view video

Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

Promoters
RGD ID:13697829
Promoter ID:EPDNEW_R8353
Type:multiple initiation site
Name:Ace_1
Description:angiotensin I converting enzyme
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Alternative Promoters:null; see alsoEPDNEW_R8354  
Experiment Methods:Single-end sequencing.
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.01094,170,755 - 94,170,815EPDNEW
RGD ID:13697846
Promoter ID:EPDNEW_R8354
Type:multiple initiation site
Name:Ace_2
Description:angiotensin I converting enzyme
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Alternative Promoters:null; see alsoEPDNEW_R8353  
Experiment Methods:Single-end sequencing.
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.01094,177,884 - 94,177,944EPDNEW

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:2493 AgrOrtholog
BioCyc Gene G2FUF-22971 BioCyc
Ensembl Genes ENSRNOG00000062101 Ensembl, ENTREZGENE, UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  ENSRNOG00055029388 UniProtKB/Swiss-Prot
  ENSRNOG00060013753 UniProtKB/Swiss-Prot
Ensembl Transcript ENSRNOT00000010627 ENTREZGENE, UniProtKB/TrEMBL
  ENSRNOT00000010627.9 UniProtKB/Swiss-Prot
  ENSRNOT00000092961.2 UniProtKB/TrEMBL
  ENSRNOT00000119881.1 UniProtKB/TrEMBL
  ENSRNOT00055050997 UniProtKB/Swiss-Prot
  ENSRNOT00060023492 UniProtKB/Swiss-Prot
Gene3D-CATH 1.10.1370.30 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
IMAGE_CLONE IMAGE:7097136 IMAGE-MGC_LOAD
InterPro Peptidase_M2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
KEGG Report rno:24310 UniProtKB/Swiss-Prot
MGC_CLONE MGC:93629 IMAGE-MGC_LOAD
NCBI Gene 24310 ENTREZGENE
PANTHER ANGIOTENSIN-CONVERTING ENZYME UniProtKB/Swiss-Prot
  ANGIOTENSIN-CONVERTING ENZYME UniProtKB/TrEMBL
  ANGIOTENSIN-CONVERTING ENZYME UniProtKB/TrEMBL
  PTHR10514 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Pfam Peptidase_M2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PharmGKB ACE RGD
PhenoGen Ace PhenoGen
PRINTS PEPDIPTASEA UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PROSITE PEPTIDASE_M2 UniProtKB/Swiss-Prot
  ZINC_PROTEASE UniProtKB/Swiss-Prot
RatGTEx ENSRNOG00000062101 RatGTEx
  ENSRNOG00055029388 RatGTEx
  ENSRNOG00060013753 RatGTEx
Superfamily-SCOP Metalloproteases ('zincins'), catalytic domain UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
UniProt A0A0A0MXV4_RAT UniProtKB/TrEMBL
  A0A8I5ZYL1_RAT UniProtKB/TrEMBL
  A0A8I6ACN5_RAT UniProtKB/TrEMBL
  A6HJZ3 ENTREZGENE, UniProtKB/TrEMBL
  A6HJZ4_RAT UniProtKB/TrEMBL
  A6HJZ5_RAT UniProtKB/TrEMBL
  ACE_RAT UniProtKB/Swiss-Prot, ENTREZGENE
  Q7TMC6 ENTREZGENE
  Q8CFN1 ENTREZGENE
  Q8CJ04_RAT UniProtKB/TrEMBL
  Q9EQM9 ENTREZGENE
UniProt Secondary Q7TMC6 UniProtKB/Swiss-Prot
  Q8CFN1 UniProtKB/Swiss-Prot
  Q9EQM9 UniProtKB/Swiss-Prot


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2021-03-09 Ace  angiotensin I converting enzyme  LOC102556346  angiotensin-converting enzyme-like  Data merged from RGD:7565702 737654 PROVISIONAL
2013-12-17 LOC102556346  angiotensin-converting enzyme-like      Symbol and Name status set to provisional 70820 PROVISIONAL
2006-03-30 Ace  angiotensin I converting enzyme (peptidyl-dipeptidase A) 1    angiotensin 1 converting enzyme  Name updated 1299863 APPROVED
2004-12-14 Ace  angiotensin 1 converting enzyme    angiotensin 1 converting enzyme 1  Name updated 1299863 APPROVED
2002-06-10 Ace  angiotensin 1 converting enzyme 1      Symbol and Name updated 70585 PROVISIONAL

RGD Curation Notes
Note Type Note Reference
gene_disease affects heart mass independent of blood pressure 1357231
gene_process functions in the renin-angiotensin system 61036
gene_process plays an important role in the regulation of blood volume and pressure 61036
gene_process level of plasma enzyme activity does not directly link to blood pressure 619632